pmc Pharmaceutics Pharmaceutics 2103 pharmamdpi pharmaceutics Pharmaceutics 1999-4923 Multidisciplinary Digital Publishing Institute (MDPI) PMC12845425 PMC12845425.1 12845425 12845425 41599180 10.3390/pharmaceutics18010074 pharmaceutics-18-00074 1 Review Recent Developments in Protein-Based Hydrogels for Advanced Drug Delivery Applications Scopelliti Giuseppe 1 https://orcid.org/0009-0009-4327-4275 Ferraro Claudia 1 https://orcid.org/0000-0002-2556-9864 Parisi Ortensia Ilaria 1 2 * https://orcid.org/0009-0001-8607-016X Dattilo Marco 1 Agu Remigius U. Academic Editor 1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, CS, Italy; giuseppe.scopelliti@unical.it (G.S.); claudia.ferraro@unical.it (C.F.); marco.dattilo@unical.it (M.D.) 2 Macrofarm s.r.l., c/o Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, CS, Italy * Correspondence: ortensiailaria.parisi@unical.it 06 1 2026 1 2026 18 1 506225 74 25 11 2025 22 12 2025 04 1 2026 06 01 2026 28 01 2026 29 01 2026 © 2026 by the authors. 2026 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license . Protein-based hydrogels are increasingly recognized as promising biomaterials for advanced drug delivery, owing to their biocompatibility, biodegradability, and ability to recreate extracellular matrix-like environments. By tailoring the protein source, crosslinking strategy, molecular architecture, and functionalization, these hydrogels can be engineered to mimic the mechanical and biological features of native tissues. Protein-derived hydrogels are currently explored across biomedical and pharmaceutical fields, including drug delivery systems, wound healing, tissue engineering, and, notably, cancer therapy. In recent years, growing attention has been directed toward natural protein hydrogels because of their inherent bioactivity and versatile physicochemical properties. This review provides an updated overview of protein-based hydrogel classification, properties, and fabrication methods. It highlights several widely studied natural proteins, such as gelatin, collagen, silk fibroin, soy protein, casein, and whey protein, that can form hydrogels through physical, chemical, or enzymatic crosslinking. These materials offer tunable mechanical behavior, controllable degradation rates, and abundant functional groups that support efficient drug loading and the development of stimuli-responsive platforms. Furthermore, we examine current advances in their application as drug delivery systems, with particular emphasis on cancer treatment. Protein-based hydrogels have demonstrated the ability to protect therapeutic molecules, provide sustained or targeted release, and enhance therapeutic effectiveness. Although critical challenges, such as batch-to-batch variability, sterilization-induced denaturation, and the requirement for comprehensive long-term immunogenicity assessment, must still be addressed to enable successful translation from preclinical studies to clinical application, ongoing advances in the design and functionalization of natural protein hydrogels highlight their promise as next-generation platforms for precision drug delivery. protein hydrogels drug delivery cancer therapy natural polymers gelatin collagen silk fibroin soy protein peptide-based hydrogels This research received no external funding. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY 1. Introduction Polymeric hydrogels are three-dimensional (3D), crosslinked networks capable of absorbing large amounts of water and biological fluids while maintaining structural integrity [ 1 ]. Their elasticity and high water content give them tissue-like mechanical properties and excellent biocompatibility, making them highly suitable for biomedical applications [ 2 ]. Over the years, hydrogels have been used across diverse fields such as drug delivery, tissue engineering, wound healing, and cancer therapy due to their tunable chemical composition and porous architecture, which enable encapsulation and controlled release of therapeutic agents [ 3 ]. Hydrogels can be classified into conventional and stimuli-responsive (“smart”) types. Conventional hydrogels typically respond to environmental changes such as pH or temperature only through simple swelling or deswelling behavior and often suffer from poor mechanical strength [ 4 ]. Smart hydrogels, by contrast, are engineered to undergo significant physicochemical changes in response to stimuli such as pH, temperature, ionic strength, light, or magnetic fields. These responsive behaviors allow precise control over drug release kinetics, localization, and timing, making them highly attractive for on-demand therapy and precision medicine [ 5 ]. Among the various hydrogel systems, protein-based hydrogels have emerged as particularly promising biomaterials due to their inherent biocompatibility, biodegradability, and biological functionality. Derived from natural or recombinant proteins such as collagen, gelatin, silk fibroin [ 6 ], albumin, and sericin, these hydrogels can closely mimic the extracellular matrix (ECM), promoting cell adhesion, proliferation, and differentiation [ 7 ]. Their mechanical and biochemical tunability enables them to function as scaffolds for tissue regeneration and as vehicles for localized, sustained drug delivery [ 8 ]. Protein-based hydrogels offer several advantages over synthetic polymer networks. Their natural origin ensures minimal immunogenicity and excellent integration with biological tissues. Moreover, their molecular structure can be modified through chemical crosslinking, enzymatic reactions, or genetic engineering, allowing the creation of stimuli-responsive systems that react to pH, temperature, or enzymatic activity. Such “smart” protein hydrogels have been exploited in cancer therapy for localized drug delivery, reducing off-target toxicity and enhancing therapeutic efficacy [ 9 ]. In wound healing applications, protein-based hydrogels provide a moist, bioactive environment that supports angiogenesis and accelerates tissue repair, especially when loaded with growth factors or antimicrobial agents [ 10 ]. Similarly, in drug delivery, they allow controlled and prolonged release of therapeutic molecules while maintaining bioactivity and minimizing systemic side effects [ 11 ]. Advances in nanotechnology and hybrid material design have further enhanced their stability and mechanical strength, extending their use to regenerative medicine, cancer immunotherapy, and targeted combination therapies [ 12 ]. Given these advancements, protein-based hydrogels represent a versatile and powerful class of biomaterials that bridge the gap between natural and synthetic systems. Their tunable properties, multifunctionality, and biological compatibility make them ideal candidates for next-generation therapeutic platforms. This review explores the design principles, modification strategies, and biomedical applications of natural protein-based hydrogels, with a particular emphasis on their role in drug delivery and cancer therapy. 2. Materials and Methods A comprehensive literature review was conducted utilizing PubMed and Scopus as primary search databases. The search was refined to include full-text, peer-reviewed research articles in English, focusing on protein-based hydrogels and their applications in drug delivery systems. To ensure relevance, only studies published between 2018 and 2025 were considered. The search strategy incorporated specific keywords, namely “hydrogel”, “protein”, “drug delivery system”, and “cancer treatment”, with query formulations tailored to each database. Relevant studies were systematically analyzed, and the extracted data were categorized into key thematic areas, including hydrogel classification, physicochemical properties, synthesis techniques, applications in drug delivery, and their role in cancer therapy. 3. Natural Polymer-Based Hydrogels Naturally derived hydrogels are increasingly regarded as the most promising materials for pharmaceutical, biomedical, and cancer therapies due to their intrinsic biofunctionality. In pharmaceutical applications, natural hydrogels act as smart drug delivery platforms, capable of encapsulating bioactive molecules and releasing them in a controlled and sustained manner, thereby enhancing drug bioavailability and reducing systemic toxicity [ 13 ]. In biomedical fields, they are highly valued for their biomimetic properties, supporting cell adhesion, proliferation, and differentiation, which are crucial for wound healing, tissue engineering, and regenerative medicine. Moreover, their tunable swelling behavior, biodegradability, and mild gelation conditions enable the encapsulation of delicate biomolecules such as proteins, growth factors, and nucleic acids without loss of activity [ 14 ]. In cancer therapy, they play an increasingly important role in localized and stimuli-responsive drug delivery, tumor targeting, and immunomodulation. Their biocompatibility and ability to respond to environmental cues allow for precise and localized release of chemotherapeutic or immunotherapeutic agents directly within the tumor microenvironment [ 15 ]. This approach enhances treatment efficacy, minimizes systemic side effects, and can be further optimized by incorporating bioactive natural components that promote tissue regeneration and immune response modulation [ 16 ]. While natural hydrogels offer compelling advantages, they often face limitations in mechanical stability, long-term durability, and batch-to-batch reproducibility. To address these issues, synthetic hydrogels, such as those derived from poly(ethylene glycol) [ 17 , 18 ], poly(vinyl alcohol) (PVA) [ 19 ], or poly(acrylamide) (PAAm) [ 20 ], are sometimes employed due to their structural precision, tunable properties, and mechanical robustness. However, synthetic systems typically lack intrinsic bioactivity and may require chemical modification or blending with natural polymers to improve cell recognition and biocompatibility. In this context, hybrid hydrogels, combinations of natural and synthetic polymers, have emerged as a versatile solution, integrating the biological advantages of natural materials with the mechanical strength and tunability of synthetic counterparts [ 21 ]. Examples such as carboxymethyl cellulose (CMC)-PEG and alginate-PVA hybrids exhibit enhanced structural stability, controlled degradation, and improved drug encapsulation efficiency, while retaining cytocompatibility and biofunctionality [ 22 , 23 ]. Although synthetic and hybrid systems help overcome some practical limitations, it is the natural-origin materials that continue to inspire the design of next-generation bioactive hydrogels, capable of mimicking natural tissues and enabling advanced therapeutic applications in drug delivery, tissue engineering, and cancer treatment. Naturally sourced biopolymers can be classified into three main categories based on their structural composition and functional properties ( Figure 1 ). The first group comprises polysaccharides, including chitosan, hyaluronic acid, and alginate, which are widely used for their biocompatibility, biodegradability, and gel-forming capabilities [ 24 ]. The second group consists of protein-based biopolymers, such as gelatin, collagen, silk, and peptide-based systems, which offer excellent mechanical strength and bioactivity, making them suitable for biomedical and pharmaceutical applications [ 25 ]. Lastly, nucleic acids, such as DNA-based hydrogels, represent an emerging class of biopolymers with unique self-assembling properties and potential applications in gene delivery, tissue engineering, and biosensing [ 26 ]. 4. Protein-Based Hydrogels Among the commonly utilized natural biopolymers for hydrogel formation, proteins like gelatin, collagen, and silk stand out due to their excellent gelation properties. Gelatin, derived from the partial hydrolysis of collagen, is rich in cell-binding RGD sequences, which enhance bioactivity and cell adhesion [ 27 ]. Collagen, as a major ECM component, provides structural integrity and biological cues crucial for cell interaction and tissue support [ 28 ]. SF offers tunable gelation kinetics, mechanical strength, and biocompatibility, though it may lack intrinsic cell adhesion motifs, which can be supplemented by combining with gelatin [ 29 ]. These proteins can form hydrogels through enzymatic, chemical, or physical crosslinking, enabling control over mechanical properties, swelling behavior, and biodegradability [ 30 ]. Such hydrogels support cell growth and proliferation due to their biomimetic environment and suitable mechanical characteristics, and they also enable encapsulation of sensitive biomolecules. Advances in crosslinking techniques have helped overcome challenges like thermal instability and rapid degradation in physiological conditions, facilitating the development of stable and functional protein-based hydrogels [ 31 ]. Building on these advances, various natural proteins have been explored as structural components for hydrogel formation, each exhibiting distinct gelation mechanisms and functional properties. For example, Wang et al. used soy protein isolate [ 32 ] to prepare an emulsion gel through a salt ion-induced method. The addition of Ca 2+ (0–7.5 mM) significantly increased the gel’s elasticity, creating a stiffer structure with better water-holding capacity. Interestingly, when the calcium concentration reached ten millimolar, the gel actually became weaker, showing a loose and non-uniform structure [ 33 ]. The characteristics of zein-based hydrogels were explored by Gagliardi et al., who found that zein could form stable dispersion gels at concentrations of 15% and 20% ( w / v ). Furthermore, high zein content promoted pseudoplastic behavior, offering a promising low-cost formulation for food production [ 34 ]. De Kruif et al. developed a transparent hydrogel using sodium caseinate (15%, w / w ) and a transglutaminase (TGase) cross-linker at pH 5.7. The resulting casein hydrogels showed good water-holding capacity [ 35 ]. Beyond these systems, other proteins such as collagen, β-lactoglobulin, α-lactalbumin, bovine serum albumin (BSA), pea protein, and lactoferrin have also been employed to develop single-protein hydrogels. These materials exhibit diverse structural and functional properties depending on their amino acid composition and molecular conformation, allowing for fine-tuning of gel strength, porosity, and biodegradability [ 36 ]. A fundamental consideration in the design of protein-based hydrogels is the selection of the protein source, which dictates the material’s bioactivity, cost, and regulatory path. While natural proteins are broadly classified into animal-derived and plant-derived categories, each presents distinct trade-offs regarding clinical translation. Animal proteins, such as collagen and gelatin, offer superior biomimetic properties and inherent cell-signaling motifs (e.g., RGD sequences), yet they often suffer from significant batch-to-batch variability and potential zoonotic risks [ 37 , 38 ]. Conversely, plant-derived proteins like soy and zein provide a more sustainable and cost-effective alternative with enhanced reproducibility and a lower immunogenic profile [ 39 , 40 ]. However, plant sources typically lack the intrinsic biological “cues” found in the animal extracellular matrix, often necessitating chemical functionalization or hybridization with synthetic polymers to achieve the mechanical robustness and cellular recognition required for advanced therapeutic applications [ 21 , 41 , 42 ]. The primary trade-offs between these biological sources, specifically regarding their clinical translatability, reproducibility, and inherent bioactivity, are compared and summarized in Table 1 . While research on interactions among protein molecules has been extensive, binary protein hydrogels are a relatively emerging area of study. McCann et al. investigated the structural and rheological characteristics of soy protein-whey protein binary hydrogels. Upon heating to 95 °C, whey protein formed the primary network structure in composite gels, and when the concentration of whey protein decreased, the gel strength weakened. Soy protein [ 32 ] acted as a filler, and hydrophobic interactions between soy and whey proteins enhanced the gels’ elastic properties [ 43 ]. Additionally, Pan and Zhong developed stable nanohydrogels through co-assembly of zein and casein. After mixing zein with sodium caseinate at pH 11.5, the pH was adjusted to 7.0 to achieve co-assembly, resulting in spherical hydrogel nanoparticles smaller than 100 nm in diameter. These nanohydrogels remained stable for 30 days at 4 °C, and the freeze-dried nanoparticles showed excellent redispersibility [ 44 ]. Sarbon et al. [ 45 ] studied the microstructural, thermal, and rheological properties of gelatin-whey protein binary gels. When combined with gelatin (3%, 5%, and 10%), the composite hydrogels exhibited significantly higher elastic moduli compared to a 10% whey protein gel alone. This could be due to synergistic intermolecular interactions between the two proteins. The gel strength, structural integrity, and thermal stability also increased with higher gelatin concentrations. At lower concentrations, gelatin filled the network space of whey protein gels, whereas at higher concentrations, it induced the formation of a continuous gel network [ 46 ]. Another significant advantage lies in the structural and functional diversity of proteins, which enables precise drug targeting. Their inherent binding sites allow drugs to interact specifically with target molecules, while various targeting ligands can be conjugated to protein-based nanocarriers to further enhance site-specific delivery. This multifunctionality makes protein nanoparticles highly effective platforms for controlled drug delivery and tissue engineering applications [ 47 ]. Despite the promising potential of hydrogel-based systems for delivery, several critical limitations hinder their clinical translation. Among the most pressing challenges are the heterogeneity in tissue integration, the propensity for cell detachment at the hydrogel interface, and the instability or premature degradation of incorporated proteins [ 48 ]. These issues can severely compromise the therapeutic efficacy and reproducibility of the delivery platform, limiting their applicability in regenerative medicine and other biomedical contexts. To effectively translate preclinical successes into meaningful clinical outcomes, future research must prioritize the development of more robust and tunable protein release systems. This includes engineering hydrogels with spatiotemporally controlled release profiles that can be tailored to specific biological cues and tissue microenvironments. Moreover, an in-depth understanding of protein conformation, molecular interactions within protein-based hydrogels, and the mechanisms governing release kinetics is critical. These insights are indispensable for optimizing bioactivity preservation and ensuring sustained delivery at therapeutically relevant concentrations [ 49 ]. Equally important is the evaluation of biocompatibility, not only in terms of cytotoxicity but also considering immune responses, degradation byproducts, and long-term tissue remodeling. By addressing these multidimensional challenges, next-generation protein-based hydrogels can be rationally designed to achieve predictable, safe, and effective in vivo outcomes [ 50 ]. 5. Synthesis Methods Protein-based hydrogels, recognized for their 3D network structures, can be synthesized through a wide range of strategies that exploit both covalent and noncovalent interactions among protein monomers and supramolecular assemblies. Depending on the synthesis method, the resulting hydrogels can exhibit distinct structural, mechanical, and functional properties, making them highly tunable for specific biomedical applications. These techniques include physical cross-linking, chemical cross-linking, enzymatic processes and self-assembly methods [ 51 , 52 ]. These synthesis strategies allow for precise control over the physical, chemical, and mechanical properties of protein-based hydrogels ( Figure 2 ). The following sections provide a detailed overview of these techniques, highlighting representative examples and their implications for drug delivery, tissue engineering, and other biomedical applications. 5.1. Physical Synthesis Methods The formation of protein hydrogels through physical methods depends on weak molecular interactions, including electrostatic forces, hydrogen bonding, and hydrophobic interactions. These approaches avoid the use of chemical cross-linkers, preserving the biocompatibility and functionality of the protein polymers [ 53 ]. For instance, hydrogen bonding between carboxylic groups of proteins like gelatin or collagen and other polymers can create pH-responsive gels with tunable mechanical properties [ 54 ]. Sun et al. investigated how charge distribution and ionic complementarity between oppositely charged peptide residues drive the lateral association of β-sheet nanofibers, forming nanostructures such as fibrils, bundles, and nanosheets. These assemblies create physically crosslinked networks through electrostatic and ionic interactions, which govern the hydrogel’s viscoelasticity and transition from viscous to self-supporting states. By tuning peptide charge patterns, ionic strength, and multivalent counterions, the density and stability of physical crosslinks can be precisely controlled, enabling biocompatible, chemically crosslinker-free hydrogels for bioengineering and biomaterial applications [ 55 ]. These physical synthesis methods are particularly advantageous for biomedical applications, enabling the development of injectable, self-healing hydrogels suitable for drug delivery and tissue engineering [ 56 ]. 5.1.1. pH-Induced Methods Beyond electrostatic interactions, pH can also induce physical crosslinking that contributes to the formation and stabilization of hydrogel networks. By carefully adjusting the pH, protein solubility, charge distribution, and conformational state can be modulated, thereby promoting controlled aggregation and hydrogel formation. For example, at acidic pH, specifically around pH 3.5, BSA adopts an F-type (partially expanded cigarlike) conformation that facilitates aggregation and gelation. This conformational change is driven by electrostatic repulsions, which cause partial denaturation and expose hydrophobic core regions that are critical for protein aggregation despite remaining electrostatic repulsions. The gelation of BSA in this F isoform can occur at room temperature within 24 h or faster at 37 °C [ 57 ]. Conversely, under alkaline conditions, BSA experiences different conformational rearrangements that facilitate the formation of fluorescent hydrogels. These structures exhibit self-healing and multifunctional properties, making them suitable for biosensing and imaging applications [ 58 ]. This pH-driven approach is not limited to BSA. Similar strategies have been successfully applied to other protein systems. For instance, Tropoelastin, the soluble precursor of elastin and a key structural protein in the human body, adopts a distinctive α-helical, polyproline type II-like conformation when exposed to alkaline conditions with pH values above 10. This structural transition is driven by changes in electrostatic interactions and hydrogen bonding patterns, which promote the alignment of hydrophobic domains and facilitate subsequent self-assembly into elastin-like fibrillar networks. Such pH-induced conformational rearrangements are critical for controlling the material properties of elastin-based hydrogels, including their elasticity, stability, and capacity for biomimetic applications [ 59 ]. 5.1.2. Metal Ion-Induced Synthesis Metal ions act as cross-linkers in protein hydrogel formation. Certain recombinant proteins interact with metal ions under light exposure, enabling the development of injectable, photoresponsive hydrogels [ 60 ]. Metal ions were able to induce crosslinking of whey protein nanofibrils, converting solutions into hydrogels. Higher-charged ions (Al 3+ , Sn 4+ ) formed gels at lower concentrations, while monovalent ions (Na + , K + ) needed higher concentrations. Additionally, multivalent ions such as Fe 3+ or Co 2+ can enhance the mechanical strength of hydrogels, supporting applications in biomedicine [ 61 ]. Whey proteins, particularly β-lactoglobulin, can form stable hydrogels upon cold gelation when pre-denatured and exposed to divalent metal ions such as Fe 2+ . The metal ions act as crosslinkers, promoting aggregation and network formation, with gel structure and stability strongly dependent on ion concentration and the pre-existing aggregation state of the proteins. Moreover, application of moderate electric fields during thermal denaturation modulates protein aggregation, enabling finer control over hydrogel microstructure and mechanical properties, thereby enhancing functional and nutritional performance [ 62 ]. 5.1.3. Temperature-Induced Synthesis Thermal processing is another effective method for hydrogel formation. For instance, Whey protein-based hydrogels, when combined with lotus root amylopectin and heated at 95 °C, show enhanced mechanical stability, due to interactions and structural changes induced by heating that improve gel formation [ 63 ]. Cold-set hydrogels differ in that they are formed at low temperatures. This method is widely used for controlled drug release applications because it allows the encapsulation of temperature-sensitive bioactive compounds without degradation. For example, cold-set gels induced by additives like glucono-δ-lactone and sodium chloride are used to embed and release drugs in a controlled manner [ 64 ]. Protein aggregates formed by thermal treatment, such as amyloid fibrils and strands, can be further manipulated at room temperature by changing pH or salt concentrations to create cold-set gels. These cold-set gels often have superior mechanical properties, higher water absorption, and require lower concentrations for gelation compared to heat-set gels. Such gels are particularly useful for immobilizing charged bioactives for targeted and controlled release [ 65 ]. 5.2. Chemical Synthesis Methods Chemical cross-linking strategies establish strong covalent bonds between protein molecules, yielding hydrogels with improved stability. Chemical crosslinkers are classified as non-zero-length, which bridge adjacent polypeptides (e.g., glutaraldehyde (GLU), polyepoxides), and zero-length, which form direct covalent bonds between nearby reactive groups (e.g., 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)) [ 66 ]. Wang et al. produced whey protein isolate fibrils via the thermal-acid method and subsequently crosslinked using citric acid (CA) to form cold-set hydrogels with tunable viscoelasticity. CA acted as a chemical crosslinker, inducing a phase transition from solution or soft-gel to rigid-gel states depending on pH and concentration. Optimal gelation occurred at 400 mmol/L CA under acidic conditions (pH 2) and at 100 mmol/L CA under neutral and alkaline conditions (pH 7–10). The enhanced storage modulus (G′) upon CA addition demonstrated its key role in promoting intermolecular crosslinking of whey protein isolate fibrils through pH-dependent interactions and charge modulation, resulting in stable, self-supporting hydrogels [ 67 ]. In another study, gelatin hydrogels were chemically crosslinked using GLU and glyceraldehyde (GAL) to study how cross-linker type, concentration, and solvent composition affect network formation and stability. GLU efficiently produced stable, highly crosslinked hydrogels under all tested conditions, whereas GAL required higher concentrations and acetone levels, likely due to acetone’s dehydrating effect, enhancing GAL reactivity through Schiff base formation with gelatin’s amine groups [ 68 ]. 5.3. Enzyme-Induced Synthesis Enzymatic cross-linking is a bioinspired method for forming protein-based hydrogels that leverages enzymes to catalyze the formation of covalent bonds between protein molecules. This approach offers several advantages over traditional chemical crosslinking, such as mild reaction conditions and enhanced biocompatibility [ 69 ]. Moreover, enzymes can target specific amino acid residues in proteins, allowing more controlled and site-specific crosslinking, therefore improving mechanical properties and facilitating functionalization. Common enzymes used include TGase, tyrosinase, and horseradish peroxidase (HRP), which catalyze cross-linking through different amino acid side chains [ 70 ]. Sahoo et al. provided a comprehensive investigation into how HRP-mediated crosslinking can be harnessed to modulate and enhance the mechanical properties of SF hydrogels through manipulation of silk extraction conditions. Their study offered direct evidence of dityrosine crosslinking catalyzed by HRP, and mechanical characterization revealed markedly increased stiffness, resilience, and β-sheet content in HRP-crosslinked silk hydrogels [ 71 ]. The study on an injectable phosphocreatine-grafted gelatin hydrogel incorporating bioactive particles underscores the potential of enzyme-catalyzed protein hydrogels as multifunctional scaffolds that facilitate synergistic tissue regeneration through precise biochemical and structural modulation. TGase-mediated crosslinking enhanced the structural and functional properties of the scaffold, facilitating mild and efficient covalent bonding and enabling the incorporation of hierarchically structured teriparatide/strontium–zinc phosphate-functionalized Zn–Cu particles without compromising bioactivity [ 72 ]. These works exemplify the advantages of enzyme-mediated crosslinking as a biologically compatible strategy for developing advanced protein hydrogels in biomedical applications. The wide range of available synthesis methods provides the ability to finely tune the properties of protein-based hydrogels, making them highly adaptable and suitable for various applications across biomedicine, drug delivery, and biomaterials science. 6. Protein-Based Hydrogels for Drug Delivery Protein-based hydrogels have emerged as highly versatile platforms for drug delivery, owing to their intrinsic biocompatibility, tunable biodegradation, and ability to form highly hydrated, 3D networks. Their natural origin provides inherent bioactivity and structural motifs that can interact favorably with therapeutic molecules, while their responsiveness to environmental cues, such as pH, temperature, or enzymatic activity, enables controlled and stimuli-responsive release profiles [ 73 ]. Moreover, the diverse chemical functionalities present in proteins allow for a broad range of crosslinking strategies, facilitating the design of hydrogels with tailored mechanical properties, stability, and drug-loading capacity. As illustrated in Figure 3 , protein-based hydrogels offer highly versatile and precisely controllable platforms for therapeutic delivery by integrating multiple release mechanisms within a single material system. The most fundamental mode of release occurs through passive diffusion ( Figure 3 A), in which drug molecules migrate from the hydrogel matrix into the surrounding tissue along a concentration gradient. This mechanism is primarily governed by the mesh size of the protein network, the molecular weight of the therapeutic agent, and the degree of hydrogel crosslinking [ 74 ]. Beyond simple diffusion, “smart” protein hydrogels are frequently engineered to respond dynamically to pathological cues. Stimuli-responsive swelling ( Figure 3 B) enables the hydrogel to undergo reversible volumetric changes in response to environmental conditions such as pH. In the context of cancer therapy, exposure to the acidic tumor microenvironment can induce hydrogel expansion, increasing mesh permeability and thereby accelerating drug release in a spatially selective manner [ 75 ]. Protein-based hydrogels also possess intrinsic biodegradability due to their peptide backbone, which can be exploited for enzyme-triggered release ( Figure 3 C). Tumor-associated proteases, often overexpressed by malignant cells, can selectively cleave peptide sequences within the hydrogel scaffold. This enzymatic erosion gradually disrupts the matrix architecture, enabling sustained and localized release of the encapsulated therapeutic payload while minimizing off-target exposure [ 76 ]. In addition to physical entrapment, therapeutics may be chemically conjugated to the protein network through cleavable linkages ( Figure 3 D). These drug–protein conjugates are designed to remain stable during circulation but dissociate upon exposure to specific chemical, enzymatic, or redox triggers present in diseased tissues. This strategy provides an additional layer of control, ensuring that drug activation and release occur only under well-defined biological conditions, thereby enhancing therapeutic efficacy and reducing systemic toxicity [ 77 ]. Beyond their tunable synthesis and release properties, protein-based hydrogels play a critical role in protecting encapsulated therapeutics during transit through harsh physiological environments, particularly in oral delivery, where labile biologics are otherwise rapidly degraded by gastric conditions [ 78 ]. This protective function is especially relevant for oral and mucosal delivery routes, where drugs are exposed to extreme pH conditions, digestive enzymes, and mechanical stress prior to reaching their site of action [ 48 ]. A key mechanism underlying this protection is the pH-dependent conformational behavior of protein networks [ 79 ]. Upon exposure to acidic environments, such as the gastric compartment (pH 1.2–2.0), which is often close to the isoelectric point (pI) of many proteins, the hydrogel undergoes pronounced structural collapse [ 80 ]. At the pI, electrostatic repulsion between protein chains is minimized, leading to network densification and a significant reduction in mesh size. This conformational collapse generates substantial steric hindrance, effectively forming a physical barrier that limits the diffusion and penetration of proteolytic enzymes, including pepsin, thereby shielding the encapsulated therapeutic cargo from premature degradation [ 81 ]. In parallel, protein-based hydrogels exhibit intrinsic buffering capacity due to the high density of ionizable amino acid side chains within their structure [ 82 ]. These functional groups partially neutralize the surrounding acidic medium, creating a localized microenvironment within the hydrogel core that is less acidic than the bulk gastric fluid. This buffering effect further contributes to preserving the structural integrity and bioactivity of pH-sensitive compounds, including fragile peptides, proteins, and hydrophobic small molecules [ 83 ]. Importantly, this protective shielding is reversible: upon transition to environments with near-neutral pH, such as the small intestine, electrostatic repulsion between protein chains is restored, promoting hydrogel re-expansion and increased network permeability. This pH-triggered swelling enables controlled and site-specific release of the therapeutic payload, either through diffusion, enzymatic erosion, or cleavage of labile drug–protein linkages [ 84 ]. Collectively, these mechanisms highlight how protein-based hydrogels function not only as delivery matrices but also as active protective carriers, ensuring drug stability during transit and enhancing therapeutic efficacy. Table 2 summarizes commonly used protein sources for hydrogel fabrication, highlighting their main features, crosslinking approaches, and therapeutic relevance in drug delivery. In the next section, we will discuss the characteristics of several representative proteins and present examples of their application as drug delivery systems, with particular emphasis on strategies developed for cancer treatment. 6.1. Gelatin Gelatin is a denatured protein obtained through the acidic hydrolysis of animal collagen. This biomolecule has been utilized for many years across the pharmaceutical, cosmetic, and food industries. One of the notable effects of gelatin is its ability to stimulate the immune system due to its denaturation process. Gelatin functions as a polyampholyte, possessing both cationic and anionic active groups, as well as hydrophobic groups, in a balanced ratio of 1:1:1. This results in a gelatin molecule with approximately 13% positive charge (from amino acids like lysine and arginine), 12% negative charge (from glutamic and aspartic acids), and 11% hydrophobic amino acids (including leucine, isoleucine, methionine, and valine) [ 85 ]. The remaining structure is primarily composed of glycine, proline, and hydroxyproline. Cationic gelatin is derived from type 1 pig skin collagen through acidic hydrolysis, while anionic gelatin is obtained from bovine collagen via hydrolysis. Gelatin is employed in various drug formulations for systemic use, serving clinically as a plasma volume expander and a stabilizer in protein formulations, vaccines, and gelatin-based sponges like gel foam [ 86 ]. The sequence of arginine-lysine-glycine is crucial in many ECM proteins, facilitating cell binding and communication by interacting with the beta subunit of integrin receptors on cell surfaces. This property gives gelatin a significant advantage over synthetic polymers that often lack specific cell recognition and binding sites. Furthermore, the active groups within gelatin allow for various chemical modifications, either directly or through different linkers, which is particularly valuable for developing targeted drug delivery systems and for attaching substantial amounts of drugs to the carriers [ 47 ]. Among its various forms, gelatin hydrogel serves as an effective sustained-release carrier due to its remarkable water retention and viscoelastic properties. It can absorb water and re-swells after being dehydrated under specific pressure conditions [ 87 ]. Current research indicates that gelatin hydrogels can be synthesized through various methods, including chemical crosslinking [ 88 ], temperature-induced crosslinking [ 89 ], photo-crosslinking [ 90 ], and enzyme-mediated crosslinking [ 91 ]. However, the properties of hydrogels produced via temperature and photo-crosslinking are often suboptimal due to varying environmental conditions [ 92 ]. Drug Delivery Applications and Cancer Treatment Owing to their intrinsic biodegradability and capacity to form stable 3D networks, gelatin-based hydrogels represent a promising class of materials for advanced drug delivery systems [ 93 ]. Recently, a phenylboronic-acid-modified gelatin methacryloyl hydrogel was developed to release epigallocatechin gallate (EGCG) in response to high reactive oxygen species (ROS) and low pH, reducing inflammation in intervertebral disk degeneration models. Phenylboronic acid was used to introduce functional groups enabling UV crosslinking and dynamic boronic ester formation. The resulting hydrogel exhibited high swelling capacity, tunable mechanical strength, and enzymatic degradability, all essential for biomedical applications, and protected nucleus pulposus cells while maintaining disk structure in vivo [ 94 ]. Besides serving as an excellent carrier for bioactive molecules, gelatin also exhibits intrinsic biological activity that promotes tissue regeneration and healing [ 6 ]. Canafístula et al. developed an innovative hydrogel system by combining gelatin with the carbohydrate-based polymer guar gum, harnessing gelatin’s natural biocompatibility and hydrophilicity alongside the mechanical robustness and chemical reactivity of oxidized guar gum crosslinked via Schiff base chemistry. The resulting hydrogels displayed tunable physicochemical properties dependent on gelatin content, including variations in gelation rate, crosslinking density, porosity, and degradation behavior. Notably, the gelatin–guar gum hydrogels exhibited strong intrinsic antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and other staphylococcal strains, even in the absence of added antibiotics. Moreover, they demonstrated excellent cytocompatibility, non-irritant behavior, and desirable functional attributes such as adhesiveness, injectability, and self-healing, underscoring their potential for topical drug delivery applications, particularly in wound healing, dermatitis, and ophthalmic treatments [ 95 ]. In another work, a dopamine- and [2-(methacryloyloxy) ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide (SBMA)-modified gelatin hydrogels were developed via an in situ dopamine-triggered reaction in the presence of zinc sulfate (ZnSO 4 ). This dual organic-inorganic network imparted biomimetic adhesion, self-healing ability, and thermal resilience. The zinc ions served both as crosslinkers and as bioactive agents, facilitating sustained antibacterial action. The gelatin matrix provided a biocompatible, hydrophilic, and porous substrate suitable for controlled release of therapeutic molecules or ions. The modified gelatin hydrogels exhibited complete antibacterial activity (up to 100%) against E. coli and S. aureus , demonstrating that gelatin’s intrinsic biopolymeric structure can be engineered for combined drug or ion release and surface antimicrobial defense [ 96 ]. Gelatin-based hydrogels have also been extensively explored as delivery platforms for anticancer drugs. Their biocompatibility, biodegradability, and ability to form stable yet stimuli-responsive networks enable controlled and localized drug release at tumor sites, minimizing systemic toxicity. Moreover, the presence of functional groups within the gelatin backbone allows chemical modification and conjugation with targeting ligands, nanoparticles, or chemotherapeutic agents, further enhancing therapeutic efficacy and specificity in cancer treatment [ 97 ]. An et al., for example, effectively encapsulated doxorubicin (DOX) and rifampicin in a dual-reinforced gelatin methacrylate (GelMA) hydrogel modified with N′-(2-nitrobenzyl)-N-acryloyl glycinamide (NBNAGA), forming a UV-crosslinked photoresponsive network. The structure combines chemical and physical crosslinking, enhancing mechanical strength and stability. Hydrophobic drugs were released in a temperature- and light-dependent manner due to the photo-cleavable nitrobenzyl groups. The hydrogels demonstrated controlled drug release and strong antibacterial activity against E. coli and S. aureus , making them highly effective for wound-healing drug delivery applications. In vivo tests in mice confirmed accelerated skin regeneration, highlighting their utility as biocompatible wound dressings with on-demand hydrophobic drug release [ 98 ]. An injectable gelatin hydrogel composite integrating Pluronic-based micelles and gelatin microgels has been synthesized to co-deliver a hydrophobic drug (curcumin) and a hydrophilic drug (5-fluorouracil, 5-FU). The gelatin component contributes biocompatibility, injectability, and biodegradability, while serving as a hydrophilic matrix capable of controlled drug encapsulation and release. The Pluronic micelles formed hydrophobic domains for curcumin entrapment, whereas the microgels encapsulated 5-FU, enabling a dual-release mechanism tailored for synergistic chemotherapy. Drug release assays confirmed sustained 5-FU release exceeding one month and controlled curcumin diffusion from the micellar domains. The composite hydrogels exhibited significant antiproliferative effects against human colorectal adenocarcinoma HT-29 cells, with improved cell death and reduced proliferation compared to single-drug systems. Gelatin’s matrix integrity and hydrophilic nature facilitated both injectability and the maintenance of drug stability, making this composite system a powerful biomaterial for localized, combinational cancer therapy [ 99 ]. The study of Ullah et al. emphasizes gelatin’s capacity to form stable, pH-sensitive networks that can protect the encapsulated oxaliplatin (OXP) through the gastrointestinal tract and enable gentle, controlled release in the colonic environment. The presence of functional groups within gelatin allowed for chemical modifications with acrylic acid (AA) and 2-acrylamido-2-methylpropane sulfonic acid (AMPS) that were able to fine-tune the hydrogel’s swelling, degradation and drug release profiles. The OXP-loaded hydrogels exhibited dose-dependent cytotoxicity against Vero, MCF-7, and HCT116 cell lines and demonstrated excellent biocompatibility and oral tolerability in animal studies. This approach aimed to improve the targeted and sustained delivery of the anticancer drug, reducing systemic side effects and increasing therapeutic efficacy in colorectal cancer (CRC) treatment [ 100 ]. 6.2. Silk Silk is a natural fibrous protein mainly produced by silkworms (such as Bombyx mori) and spiders. It possesses a range of characteristics that make it an ideal material for biomedical applications. It is biocompatible and enzymatically biodegradable, ensuring safe integration into biological systems without inducing adverse reactions [ 101 ]. Additionally, silk-based materials exhibit low immunogenicity and are nontoxic, making them suitable for medical use [ 102 ]. One of silk’s key advantages is its exceptional mechanical stability, along with its controllable format and size. Its reversible swelling behavior allows for storage in a dried state, thereby expanding its potential for functionalization, fabrication, and processing into robust biomaterials. The unique physicochemical properties of silk stem from the structural organization of its proteins at the primary and secondary levels. The interplay between highly repetitive hydrophobic crystalline regions and hydrophilic non-crystalline domains results in a hierarchical structure that drives self-assembly. This structural organization leads to strong physical interactions and outstanding mechanical properties, including high strength and toughness [ 103 ]. Furthermore, the hydrophobic domains within silk proteins, specifically, the GAGAGS motif in silkworm silk and the poly(GA) and poly(A) sequences in spider silk, contribute to its crystalline content. These domains play a crucial role in enhancing hydrophobic interactions with drug molecules, thereby enabling precise control over drug loading and release kinetics. Advancements in genetic engineering have further expanded the versatility of silk-based biomaterials. By modifying synthetic silk genes, researchers can regulate the balance between crystalline and noncrystalline domains, thereby fine-tuning both the mechanical properties of silk and its drug-binding capabilities. This ability to manipulate silk’s molecular structure opens new possibilities for optimizing its application in controlled drug delivery systems [ 103 , 104 ]. Silk consists primarily of two proteins: fibroin, which forms the structural core of the fiber, and sericin, a glue-like coating that binds the fibroin filaments together. Fibroin features a distinctive molecular architecture enriched with repetitive amino acid sequences (chiefly glycine, alanine, and serine) that assemble into tightly packed antiparallel β-sheet crystals. This ordered structure imparts silk with its exceptional mechanical strength, toughness, and biocompatibility [ 105 ]. Within SF, the protein chains adopt β-sheet secondary structures, providing rigidity and stability while retaining a degree of flexibility. In contrast, sericin is a hydrophilic protein rich in polar groups, serving both as an adhesive and a protective layer for the fibroin core [ 106 ]. SF’s excellent histocompatibility and low immunogenicity make it unlikely to provoke significant immune responses, and it possesses a degree of biodegradability, typically breaking down into amino acids or oligopeptides. The degradation products are not harmful to the body and can provide nutritional and reparative benefits to surrounding tissues, leading to its widespread application in tissue engineering [ 17 ]. SF hydrogels can be synthesized using both physical and chemical crosslinking methods. Physical crosslinking leverages the silk protein’s sensitivity to various molecular conditions (such as pH, shear, and vibration) to induce the formation of beta-folded structures that yield hydrogels. Common physical crosslinking techniques involve elevated temperatures and adjustable pH levels, often utilizing cyclone processing or ultrasonic processing [ 107 ]. While SF hydrogels produced through physical crosslinking exhibit considerable strength, they have drawbacks, including prolonged crosslinking times and brittleness. Chemical crosslinking for SF hydrogels involves creating covalent bonds between polymer chains [ 108 ]. Commonly employed methods include the use of crosslinking agents, light exposure, and enzymatic reactions [ 109 ]. Sericin, another silk-derived protein, encases SF and offers protective benefits. The primary distinction between the two is that SF swells in water but does not dissolve, while sericin can dissolve in hot water [ 110 ]. Research into sericin has unveiled its considerable advantages as a biomaterial, including its stable source, strong processability, hydrophilicity, low immunogenicity, ability to promote cell proliferation, inhibition of tyrosinase activity, and controllable degradation. In the context of sustained-release drug delivery systems, sericin can be engineered into hydrogels using a range of strategies, including physical, chemical, and photo-crosslinking methods. The most common chemical approach involves GLU as a crosslinking agent [ 111 ]. Alternatively, based on the principle that proteins are insoluble in ethanol, pure sericin hydrogels can be fabricated through ethanol-induced precipitation combined with ultrasonic treatment [ 112 ]. Moreover, photo-crosslinking has also been explored: for example, Qi et al. developed an in situ hydrogel by UV-induced photo-crosslinking of methylacryloyl-functionalized sericin, demonstrating a controllable and biocompatible approach to hydrogel formation [ 113 ]. Gels derived from this protein exhibit sensitivity to pH variations, making them suitable for developing smart drug delivery systems. Drug Delivery Applications and Cancer Treatment Silk-based hydrogels have emerged as versatile and biocompatible platforms for drug delivery, offering tunable mechanical properties, controlled degradation, and the ability to sustain the release of therapeutic agents over prolonged periods. Recently, a soft hydrogel was formulated at room temperature by blending sericin and polycaprolactone (PCL), achieving a porous and non-Newtonian rheological system with good absorption capacity. The internal morphology of such silk-based systems, as characterized by scanning electron microscopy ( Figure 4 A), typically reveals an interconnected porous architecture. This porosity is critical not only for drug loading but also for providing the gas exchange necessary for tissue regeneration. In these blends, sericin’s inherent properties contributed importantly to the hydrogel’s antibacterial efficacy against both Gram-positive and Gram-negative bacteria, further enhanced when loaded with the model drug diclofenac sodium. From a mechanistic standpoint, these hydrogels demonstrated substantial swelling and sustained controlled release behavior. To quantitatively evaluate these profiles, experimental data are often fitted to mathematical models as shown in Figure 4 B. For silk-PCL systems, the release kinetics typically aligned with the Korsmeyer–Peppas model, where the release exponent often indicates an anomalous transport mechanism, a combination of Fickian diffusion through the sericin-rich pores and the slow erosion of the PCL-stabilized matrix. This sustained release, coupled with the natural bioactivity of silk, makes these platforms particularly promising for chronic wound healing and long-term localized drug delivery application [ 114 ]. Ghorbani et al. combined alginate and SF, crosslinked through both ionic gelation and Schiff-base reactions, resulting in a scaffold with enhanced mechanical strength, stability, and biocompatibility. Although primarily developed for bone tissue engineering, the system’s properties (porosity, sustained degradation, and tunable crosslinking density) also make it suitable for localized drug delivery, including anticancer therapies at bone defect sites. SF contributed by forming β-sheet domains that stabilized the network and modulated drug binding, enabling controlled, site-specific release of therapeutic molecules [ 115 ]. Peng et al. developed an SF-based hydrogel that can self-assemble into injectable, porous networks under physiological conditions. Their study emphasizes the biocompatibility, biodegradability, and excellent mechanical properties of the protein, making it suitable for minimally invasive delivery. The hydrogel incorporates iodine as a therapeutic agent, which, when released in a sustained manner, induces apoptosis in osteosarcoma cells through mechanisms involving ROS and apoptosis pathways. The hydrogel’s X-ray visibility allowed for image-guided injection directly into tumor sites, facilitating precision treatment. SF formed a stable, biocompatible, and imageable hydrogel, able to combine therapeutic and diagnostic functionalities in a single system, making it a promising platform for focal osteosarcoma therapy [ 116 ]. Besides bioactive molecules for tumor therapy, silk-based hydrogels have also been explored as delivery systems for conventional chemotherapeutic agents, offering both local administration methods, such as intratumoral and transdermal delivery, and systemic approaches via intravenous injection, and in various formats [ 117 ]. For localized drug delivery, 3D silk implants have demonstrated effective control over drug release rates, including injectable hydrogels designed for sustained drug administration [ 118 , 119 ]. For systemic delivery, the study of Fernández-Serra et al. describes SF hydrogels exhibiting notable permselectivity, enabling controlled diffusion of drug molecules and making them highly effective carriers for advanced neurotherapeutic delivery. Their tunable network structure allowed precise regulation of drug permeation, ensuring sustained and targeted release to neural tissues while minimizing systemic exposure. Such hydrogels protected encapsulated agents from premature degradation, maintained therapeutic concentration at disease sites, and supported localized administration of chemotherapy drugs for neuro-oncological applications. This selective barrier function enhanced efficacy and safety in complex neural environments [ 120 , 121 ]. Jaiswal et al. developed injectable hydrogels composed of a blend of Bombyx mori silk fibroin (BMSF) and Antheraea assamensis silk fibroin (AASF) to evaluate their potential for localized drug delivery in post-lumpectomy breast cancer treatment [ 122 , 123 ]. A 3D in vitro lumpectomy model using the MDA-MB-231 cell line was designed to assess the efficacy of these hydrogels in delivering DOX for the targeted elimination of residual breast cancer cells. Additionally, the potential for adipose tissue regeneration in the lumpectomy site was explored by incorporating dexamethasone (DEX) into the hydrogel system. Rheological analysis demonstrated that the BMSF/AASF blended hydrogels possessed viscoelastic properties and injectability suitable for minimally invasive applications. The slow and sustained release of DOX from the hydrogels resulted in effective cytotoxicity against MDA-MB-231 cells, as confirmed by in vitro studies. These findings highlight the potential of the developed injectable hydrogels as a dual-purpose system for localized anticancer drug delivery and post-lumpectomy breast reconstruction [ 122 ]. A. Gangrade and B.B. Mandal developed an innovative porous silk scaffold designed to integrate both a soft hydrogel matrix and stomach cancer (AGS) cells within a single platform. The AGS cells were seeded around the periphery of the scaffold, where they occupied the porous structure and formed 3D spheroids. Meanwhile, an injectable silk hydrogel embedded with cisplatin-loaded nanocomposites was introduced into the central cavity of the scaffold to assess its extended bioactivity over 11 days. This strategic arrangement allowed for sustained cisplatin release, ensuring prolonged exposure of the drug to the surrounding spheroids for enhanced therapeutic efficacy. To simulate cancer recurrence, AGS cells were reintroduced on the second day of treatment. Experimental results demonstrated that the nanocomposite silk hydrogel significantly prolonged the stability and cytotoxic effects of cisplatin. Consequently, the reseeded AGS cells were unable to survive on the scaffold, highlighting its potential to prevent tumor relapse [ 124 ]. These approaches underscore the effectiveness of the engineered silk scaffolds in supporting targeted and sustained chemotherapy while minimizing the likelihood of cancer recurrence. 6.3. Soy Protein Soy protein [ 32 ] is a naturally derived polymer extensively explored as a foundational material for the development of polymeric networks designed for drug delivery applications. Its widespread availability, favorable water solubility, and exceptional biocompatibility, biodegradability, non-immunogenicity, and anti-carcinogenic properties make it a promising candidate for biomedical use [ 125 ]. Extracted from an abundant, cost-effective, and renewable plant-based resource, SP consists primarily of two globular protein subunits: 7S (β-conglycinin) and 11S (glycinin) [ 126 ]. Due to its inherent bioactivity, SP has found extensive applications in various fields, including the production of adhesives, hydrogels, plastics, films, coatings, and emulsifiers. Additionally, it is widely investigated for its potential in biotechnology and biomedical engineering [ 127 ]. Compared to other biodegradable polymers and natural proteins, the SP matrix exhibits distinctive advantages, such as improved water resistance, prolonged storage stability, and structural robustness. These characteristics position SP as a valuable material for the design of novel biomaterials and medical devices, further enhancing its potential in biotechnology and biomedical research [ 128 ]. SP isolate [ 32 ] is the enriched form of soy protein, offering a balanced mix of polar, non-polar, and essential amino acids, making it suitable for use in various pharmaceutical applications. In aqueous environments, SPI proteins assemble into spherical structures with a hydrophilic outer shell and hydrophobic core, facilitating stability and functionality. Upon the introduction of precipitating agents or crosslinkers, SPI can form diverse structures, including microspheres and hydrogels, expanding its potential as a carrier in drug delivery systems. The distinctive 11S/7S globulin ratio further influences the emulsifying, gelling, and foaming properties relevant for biomedical uses [ 129 ]. Drug Delivery Applications and Cancer Treatment The integration of SP-based hybrid hydrogels into drug delivery applications has gained significant attention in recent years, owing to their renewable, biodegradable, and biocompatible nature. Additionally, their tissue-mimicking properties make them highly desirable in biomedical engineering [ 130 ]. Singhal et al. developed a pH-sensitive, biocompatible hydrogel by grafting 2-hydroxyethyl methacrylate (HEMA) onto SPI. This grafting approach imparted significant stimulus-responsive behavior to the SP hydrogel, making it adaptable for controlled drug delivery applications in biomedical contexts. SIP served as the core biopolymer matrix in these hydrogels, supporting excellent cell adhesion and growth. They used paracetamol as the model drug for loading and release experiments, with results showing effective encapsulation and sustained release and demonstrating its suitability for pH-sensitive, biomedical drug delivery applications [ 131 ]. Another study reports the development of SPI-based hydrogels for probiotic delivery. The hydrogels were formed through enzymatic crosslinking by microbial transglutaminase (mTGase), creating a biocompatible and stable network under mild conditions that preserves probiotic viability. The authors used ultrasonic treatment to enhance protein dispersion and gel uniformity, resulting in a denser and more elastic structure with improved mechanical strength. The addition of citrus pectin further stabilized the matrix and contributed to protection against acidic and UV stress during gastrointestinal transit, confirming the platform’s promising capacity for targeted oral delivery of probiotics and other sensitive bioactives [ 132 ]. A nanocomposite hydrogel combining SP and PAAm was synthesized via in situ polymerization. The SP served as a natural, biodegradable, and biocompatible matrix, while the PAAm provided mechanical strength and enhanced water absorption properties. Crucially, this hydrogel demonstrated sustained and controlled release of the antibiotic ciprofloxacin, with drug release rates reaching up to 95% in vitro. The network structure of the hydrogel, characterized by good porosity and layered morphology, supported effective drug loading and gradual release. This study highlights the potential of SP-based nanocomposite hydrogels as versatile drug delivery systems, combining natural protein properties with synthetic polymer advantages for controlled antimicrobial therapy. The hydrogel’s pH-responsive swelling behavior further enables targeted release applications [ 133 ]. Building upon the general advances in drug delivery, particular attention has been devoted to the use of SP–based hydrogels for the targeted and controlled delivery of both hydrophobic and hydrophilic chemotherapeutic agents, aiming to enhance antitumor efficacy while minimizing systemic toxicity. Their natural gelation properties and capacity for modification allow for controlled drug release profiles, improving drug stability and targeting precision in cancer therapy [ 134 ]. Viale et al. developed the first SPI-based hydrogel incorporating DOX-loaded liposomes (LIPO-DOX) for the localized treatment of recurrent glioblastoma. The implantable, in situ-gelling hydrogel was designed to conform to the post-surgical cavity, enabling sustained drug release while being biodegradable, thus avoiding the need for surgical removal. Complete degradation was estimated to occur within two months. The encapsulation efficiency of LIPO-DOX was high (~94%), and the liposomes exhibited a characteristic “coffee bean” morphology within the protein matrix. Release studies showed gradual liposome diffusion over 48 h, and in vitro assays on U87-MG glioblastoma cells confirmed that released LIPO-DOX maintained pharmacological activity, effectively reducing cell viability in a dose-dependent manner [ 135 ]. 6.4. Casein Caseins represent the predominant protein group in milk, comprising approximately 80% of its total protein content. These proteins are encoded by multiple genes clustered on the same chromosome [ 136 ]. The primary casein types include αS1-casein (Bos d 9), αS2-casein (Bos d 10), β-casein (Bos d 11), and κ-casein (Bos d 12), contributing approximately 40%, 12.5%, 35%, and 12.5% of the total casein fraction, respectively. Due to genetic polymorphisms, caseins exhibit high structural variability, resulting in multiple protein variants. These variations arise from single amino acid mutations, deletions of peptide segments of varying lengths, or post-translational modifications such as glycosylation, phosphorylation, and partial hydrolysis, all of which influence their physicochemical properties and allergenic potential [ 137 ]. As phosphoproteins, caseins contain between one and eleven phosphate groups, which form ester bonds primarily with serine hydroxyl residues. The number of phosphorylated serine residues within the polypeptide chains determines their affinity for calcium ions [ 138 ]. Functionally, αS1-, αS2-, and β-caseins serve as calcium-binding proteins, whereas κ-casein plays a crucial role in stabilizing the casein micellar structure [ 139 ]. Notably, casein demonstrates remarkable ion-binding capacity, surface activity, self-assembly behavior, emulsification abilities, and gel-forming properties, all of which contribute to its potential as a controlled drug release system [ 47 ]. Gelation of casein typically involves pH-triggered mechanisms where changes in pH alter protein charge and promote aggregation and network formation. Enzymatic crosslinking using TGase has been demonstrated to enhance the gel network by increasing fractal dimension and creating a tighter, more stable matrix [ 140 ]. These hydrogels show advantageous properties such as mechanical strength, stability, biocompatibility, and controlled drug release behavior. Functionalization with other polymers like konjac glucomannan or polyglutamic acid (PGA) further modulates these properties, enabling tailored biomedical applications, including drug delivery and tissue engineering [ 141 , 142 ]. Drug Delivery Applications and Cancer Treatment As the primary protein component of milk, casein has gained increasing recognition for its versatility in drug delivery systems. Its key advantages include cost-effectiveness, stability, and the ability to encapsulate a diverse range of bioactive molecules. Due to its distinctive physicochemical characteristics, casein has been extensively studied for controlled drug release. It possesses a strong affinity for binding various ions and bioactive compounds, exhibits outstanding emulsification and gelation capabilities, and retains water effectively, making it a valuable component for pharmaceutical formulations [ 143 ]. Despite its advantages, casein-based drug delivery systems are not without challenges. Potential immunogenic concerns, including allergenic responses and immunosuppressive effects, must be taken into account. While casein undergoes enzymatic breakdown into amino acids in the gastrointestinal tract, intact casein proteins may still trigger immune responses, particularly in intravenous applications [ 144 ]. Wang e t al. explored the enzymatic crosslinking of casein with γ-polyglutamic acid (γ-PGA) to form hydrogels using mTGase and they tested both hydrophilic vitamin B12 and hydrophobic aspirin as model drugs. Casein served as a natural protein matrix with abundant reactive glutamine and lysine residues that were targeted by mTGase to create covalent bonds, resulting in a stable, biocompatible hydrogel network. This enzymatic gelation method provided mild reaction conditions and precise control over hydrogel properties, making it highly suitable for encapsulating and delivering various bioactive drugs. The resulting casein-γ-PGA hydrogels exhibited controlled drug release profiles and enhanced mechanical stability, positioning them as promising candidates for sustained and targeted drug delivery applications [ 145 ]. Casein has been combined with other natural proteins, such as gelatin, to enhance the mechanical strength, stability, and functional properties of the resulting hydrogels. Zhang et al., for example, developed a biocompatible and biodegradable hydrogel composed of gelatin and casein proteins, enzymatically crosslinked to form a natural hydrogel network for wound dressing applications. An innovative feature of this hydrogel system is its on-demand tissue adhesion capability, mediated by the application of chitosan solution, which enhances the hydrogel’s adhesion strength and allows easy control and activation at the wound site. The hydrogel’s degradation rate and drug release profile could be finely tuned by adjusting enzymatic crosslinking conditions. For drug delivery, the study used tetracycline hydrochloride as a model drug loaded into the hydrogel matrix. The casein-containing hydrogel provided effective antibiotic delivery directly at the wound site, offering antibacterial properties essential for preventing infection in wound healing. The drug-loaded hydrogel demonstrated excellent blood compatibility, cell compatibility, and successfully promoted the healing of infected wounds in animal models [ 146 ]. Casein-based systems have shown great potential as carriers for the controlled delivery of antitumor drugs. Mehryab et al. [ 147 ] designed a casein-based hydrogel using an acid-induced gelation technique to achieve a controlled release of crocin, the primary carotenoid in saffron, known for its multiple therapeutic benefits, particularly its strong anti-tumor effects across various tissues and organs [ 148 ]. These hydrogels exhibited non-Newtonian pseudoplastic behavior. Among the different formulations, the hydrogel with the lowest casein-to-crocin weight ratio (10:1) demonstrated the highest crocin loading capacity, the greatest swelling in simulated saliva fluid within the first hour, and the most significant crocin release (58.07% over 24 h). This enhanced release profile was attributed to the increased porosity of the hydrogel structure. Regardless of formulation differences, all casein-based hydrogels enabled a sustained in vitro release of crocin [ 147 ]. In combination with alginate, casein has been used to incorporate green-synthesized selenium nanoparticles, which have known anticancer properties. The unique amalgamation enhances targeted cancer therapy by promoting sustained release of therapeutic selenium nanoparticles directly to tumor sites, thereby improving the therapeutic index while minimizing systemic toxicity. Casein’s amphiphilic nature and functional groups supported stable hydrogel formation with alginate and efficient encapsulation and retention of selenium nanoparticles, contributing to prolonged drug release and enhanced bioavailability at the cancer site. The green synthesis of the nanoparticles within this casein-alginate hydrogel reduced harmful chemical residues, aligning with eco-friendly and biocompatible treatment goals. Overall, this platform leverages casein hydrogel’s natural properties and selenium’s anticancer efficacy to offer a promising, safer, and effective targeted therapy strategy for cancer treatment [ 149 ]. 6.5. Whey Protein Whey proteins, derived from milk, exhibit outstanding functional, biological, and nutritional properties, making them highly suitable for various biomedical and food applications. The primary constituents of whey proteins are globular proteins, including β-lactoglobulin (β-LG), α-lactalbumin, and BSA [ 150 ]. Extensive research has demonstrated the potential of whey protein-based products, such as whey protein isolate (WPI) and whey protein concentrate (WPC), as well as some specific components, in the development of protein-based hydrogels. These hydrogels have been widely investigated for their ability to encapsulate and deliver bioactive molecules and micronutrients. Their formulation can be achieved using whey proteins in their native or aggregated states (such as fibrils and microgels), either alone or in combination with other materials, enhancing their functional versatility [ 151 ]. Whey protein amyloid fibrils, for example, have been used to create composite hydrogels for effective drug delivery, providing a robust and biofunctional scaffold due to their highly ordered beta-sheet-rich structure, which enhances hydrogel mechanical strength and stability. In this system, the whey protein fibrils were combined with gliadin nanoparticles to form a hybrid hydrogel matrix that exhibits tunable viscoelastic properties, allowing controlled encapsulation and release of hydrophobic bioactive compounds like curcumin. The nanostructured fibrillar network improved the hydrogel’s ability to sustain drug release while protecting curcumin from degradation. This approach demonstrated how whey protein-based hydrogels can be engineered at the nanoscale to optimize drug loading, release kinetics, and structural integrity, making them promising platforms for delivering poorly soluble therapeutic agents in biomedical applications [ 152 ]. WPI is a more purified form, containing 90% or more protein, obtained through additional filtration or ion-exchange steps that remove most of the fat and lactose. As a result, WPI has a cleaner composition and is suitable for applications requiring high protein purity, including clinical nutrition, sports supplementation, and biomaterial development. In research, particularly in the formulation of protein-based hydrogels or drug delivery systems, WPI is often preferred over whey concentrate because its higher purity and consistent composition improve the reproducibility of gelation behavior, mechanical properties, and functional performance [ 153 ]. Moreover, WPI has been widely investigated due to its ability to form long and slender protein nanofibrils (PNFs) with well-defined morphologies that frequently display strong interactions with their surroundings, resulting in the formation of hydrogels with potential for diverse applications, including biomedical, optoelectronic, and hybrid organic–inorganic materials, as well as templates for nanowire fabrication. These fibrils typically exhibit a width of approximately 4 nm and can extend to several micrometers in length. In comparison, other proteins, such as meat hemoglobin, rice globulin, and SPI, tend to produce shorter fibrils with less well-defined structures [ 61 , 154 ]. Drug Delivery Applications and Cancer Treatment Whey protein-based hydrogels have demonstrated a remarkable capacity for releasing probiotics in the gastrointestinal tract. Whey protein hydrogels exhibit tunable viscoelasticity, pH- and temperature-responsive swelling, and efficient encapsulation properties due to the availability of reactive amino groups that enable physical or enzymatic crosslinking. These attributes make them effective in controlling the release of bioactives and sensitive therapeutics, similar to their role in safeguarding probiotics against gastrointestinal degradation. Moreover, whey protein hydrolysates, rich in bioactive peptides, can enhance the release kinetics and bioavailability of encapsulated drugs through improved solubility and degradability. The findings revealed that the survival rate of probiotics encapsulated within these hydrogels exceeded 96%, in stark contrast to the mere 37.43% survival rate observed for free probiotics [ 155 ]. In a separate study, Feng et al. developed an innovative double-layered encapsulation system for Lactobacillus plantarum, which significantly improved the thermal stability and tolerance of the probiotics in simulated gastrointestinal conditions [ 156 ]. The incorporation of BSA into β-LG amyloid fibril-based hydrogels demonstrates a tunable approach to modulating the structural and functional properties of whey protein hydrogels for drug delivery. BSA enhances β-LG fibrillogenesis and stabilizes the fibrillar network against pH-induced disruption, leading to a more compact and homogeneous microstructure. However, its intercalation between fibril chains may reduce mechanical strength by limiting fibril entanglement. In drug release studies using riboflavin as a model compound, release kinetics were governed by fibril content and BSA-Riboflavin binding affinity. Under enzymatic digestion, the degradation of BSA and the hydrogel matrix diminished the contribution of binding affinity, leaving fibril density as the dominant factor controlling release. Overall, BSA acts as a modulatory component within β-LG-based hydrogels, enabling fine control over network architecture, mechanical integrity, and release behavior, highlighting a versatile strategy for tailoring whey protein hydrogels in controlled delivery systems [ 157 ]. In combination with gelatin, WPI has been used to encapsulate and deliver N-acetylneuraminic acid (NeuAc), a bioactive compound closely related to sialic acids, for drug delivery applications. WPI’s excellent biocompatibility and gelation properties are leveraged to enhance mechanical strength, encapsulation efficiency, and controlled-release behavior within the hydrogel network. The hydrogel’s drug release profile can be tuned by modifying the gelatin-to-WPI ratio, enabling pH-responsive and sustained release patterns particularly suited for oral administration. This combination allows the hydrogel to protect the bioactive compound as it passes through the gastrointestinal tract and then facilitates controlled, site-specific release in response to intestinal pH. The approach validates the potential of whey-protein-based hydrogels as a versatile platform for drug delivery, promoting improved bioavailability and stability of loaded compounds during gastrointestinal transit [ 158 ]. WPI hydrogels have also been explored for the delivery of therapeutic compounds targeting tumor treatment. Recent studies have shown that WPI-based hydrogels can effectively encapsulate hydrophobic antitumor molecules such as cannabidiol (CBD), enabling controlled, pH-responsive release within gastrointestinal regions commonly affected by cancers like colorectal cancer. A central component of this work involved assessing hydrogel performance under simulated digestive conditions to determine their suitability as drug-delivery platforms for CRC. Release profiling and cell-viability assays confirmed that CBD preserved its biological activity after encapsulation, underscoring the protective role of the WPI matrix. Notably, the hydrogels remained stable in stomach-like environments, withstanding acidic pH and enzymatic degradation to prevent premature CBD release. In contrast, both matrix degradation and CBD release increased markedly under intestinal conditions, supporting their potential for targeted delivery [ 159 ]. Furthermore, previous research has shown that CBD exerts antiproliferative effects on HT29 CRC cells in vitro [ 160 ]. Therefore, to assess the efficacy of WPI-CBD hydrogels in impacting cell viability, HT29 cells were treated for 72 and 96 h. While no significant effects were observed at 72 h, by 96 h, a notable reduction in cell viability was recorded—20.4% (WPI-CBD2), 18.3% (WPI-CBD4), and 21.8% (WPI-CBD5) ( p < 0.05). Given these results, in combination with the observed bioactivity retention, the study concluded that WPI hydrogels hold strong potential as an effective delivery platform for hydrophobic molecules in CRC treatment. These findings support the continued investigation of WPI-CBD hydrogels as a promising candidate for CRC therapy [ 159 ]. The integration of tannic acids (TAs) into biomaterials has been associated with reduced tumor necrosis factor levels [ 161 ] and suppression of inflammatory cytokines, motivating their use in anticancer applications [ 162 ]. Building on these properties, Mayorova et al. developed pH-sensitive, cytocompatible hydrogels that combine TAs with whey protein isolate (WPI). Two TA derivatives. Polygalloyl glucoses (ALSOK 02) and polygalloyl quinic acids (ALSOK 04) were compared, differing in molecular weight and structure. The hydrogels exhibited marked pH-responsive behavior: at acidic pH (5), significant TA release occurred due to protein dissociation and protonation. This is particularly relevant for cancer therapy, as both tumor microenvironments and endosomal compartments are typically more acidic than healthy tissues. The pH-dependent release profile supports their suitability as localized scaffolds for gastrointestinal cancers, where pH ranges from acidic to basic. Cytotoxicity studies using Hep-2 laryngeal cancer cells revealed minimal effects for WPI-only hydrogels, while TA-containing formulations significantly reduced metabolic activity in a concentration-dependent manner. Hydrogels with the highest TA/WPI ratio decreased cell viability by 50% at 24 h and 80% at 48 h. Overall, WPI hydrogels incorporating TAs (3 mg/mL and TA/WPI ratio 0.075) were identified as the most promising formulation for sustained anticancer activity [ 163 ]. Together, these findings underscore whey-protein-based hydrogels as a highly versatile and tunable platform capable of protecting sensitive bioactives, enabling targeted and sustained release, and supporting promising therapeutic applications ranging from probiotic delivery to localized anticancer treatment. 6.6. Collagen Collagen is a key structural protein found in the bodies of vertebrates and is the most abundant protein in mammals, constituting about 20–30% of total body protein. Its fundamental structure consists of tropocollagen, which comprises three intertwined strands that form a triple helix, interconnected by various non-covalent bonds. Ultimately, collagen is formed through covalent crosslinking of tropocollagen molecules [ 164 ]. Due to its excellent biocompatibility, minimal immune system stimulation, and biodegradability, collagen is extensively utilized in medical applications [ 165 ]. Collagens, especially type I collagen, account for approximately 90% of the protein found in human connective tissues and are commonly utilized to create single-component hydrogels [ 166 ]. At a neutral pH, collagen fibrils can self-assemble into bundled fibers, which can crosslink to form matrices. When combined with a water-based solvent system, these matrices ultimately develop into hydrogels [ 167 ]. Collagen is a key structural protein found in the ECM of vertebrates, present in tissues such as skin, connective tissue, bone, and cartilage. Due to its biological origin, collagen has low immunogenicity, meaning it is unlikely to trigger significant inflammation or immune responses when introduced into body tissues [ 168 ]. Collagen hydrogels mimic the ECM’s structure, making them closely resemble natural biological tissues. They can be degraded by collagenase within the body, allowing them to fully utilize their biological functions. Current methods for preparing collagen hydrogels include self-assembly and chemical crosslinking [ 169 ]. Collagen self-assembly involves the organization of collagen fibers, where molecules connect end-to-end in a staggered manner, trapping solvent within the structure and preventing free flow. This method primarily relies on noncovalent interactions, which can result in suboptimal performance. In contrast, chemically crosslinked collagen hydrogels are created through covalent bonding, often employing small-molecule aldehydes or epoxides as crosslinking agents. While these chemically crosslinked hydrogels exhibit good elasticity, they may lack the softness found in hydrogels produced via self-assembly [ 170 ]. Collagen hydrogels are often injectable under physiological conditions and can be combined with other biomolecules, like hyaluronic acid, to enhance their properties for applications in cartilage, bone, and skin regeneration [ 171 ]. Recent advances include multifunctional collagen hydrogels endowed with antibacterial, conductive, or antioxidant functionalities to improve wound healing and tissue repair outcomes [ 172 , 173 ]. The concentration of collagen and the degree of crosslinking significantly influence the hydrogel’s stiffness, porosity, and biological performance, making these materials highly versatile and customizable for various regenerative medicine and drug delivery systems [ 174 ]. This versatility, combined with collagen’s inherent biological advantages, underscores its widespread use in medical fields such as tissue engineering, wound healing, and controlled drug release. Drug Delivery Applications and Cancer Treatment Collagen-based hydrogels have emerged as highly promising biomaterials for drug delivery, offering a unique combination of biocompatibility, tunable structure, and physiological relevance that enables precise and efficient therapeutic release [ 175 ]. Biocompatible hydrogels comprising collagen, chitosan, and polyurethane have shown significant potential for wound healing and controlled drug release, particularly leveraging the properties of collagen as a core biomaterial. Collagen forms a natural, biodegradable, and biocompatible matrix that mimics the extracellular environment, promoting cell adhesion, proliferation, and tissue regeneration. When combined with chitosan and polyurethane, these hydrogels exhibit enhanced mechanical strength, stability, and antibacterial properties due to chitosan’s intrinsic antimicrobial effects. These collagen-based hydrogels demonstrated controlled release profiles, exemplified by the release of ketorolac (a non-steroidal anti-inflammatory drug) under physiological conditions (pH 7, 37 °C). This controlled release capacity, combined with the biological activity of the hydrogel, supports its use as a smart wound dressing material that not only protects the wound but also provides localized, sustained therapeutic delivery to aid healing [ 176 ]. The versatility of collagen-based hydrogels is further demonstrated in complex regenerative tasks, such as peripheral nerve repair. A recent study reported a collagen–reduced graphene oxide (COL–rGO) biocomposite hydrogel synthesized via horseradish peroxidase/hydrogen peroxide–mediated crosslinking, yielding an injectable, mechanically reinforced, and cytocompatible network with controlled degradation. The COL–rGO matrix supported fibroblast adhesion and proliferation in vitro and promoted wound-healing–related marker expression. In vivo, it accelerated wound closure, enhanced re-epithelialization, and increased collagen deposition compared with pristine collagen gels, demonstrating that conductive nanofillers and mild enzymatic crosslinking can significantly enhance the bioactivity of collagen hydrogels for chronic wound treatment [ 32 ]. Fan et al. [ 177 ] engineered a hydrogel system using collagen derived from tilapia skin combined with chitosan (HCC) to explore its efficacy as a carrier for therapeutic nanobodies. Their investigation centered on two nanobodies: 2D5, which specifically binds to carcinoembryonic antigen (CEA), and KPU, targeting programmed death-ligand 1 (PD-L1). Among the different formulations, HCC10, comprising equal concentrations (10 mg/mL) of collagen and chitosan, displayed the highest stability. To evaluate controlled nanobody release, they examined the hydrogel’s behavior across varying pH levels, reflective of physiological conditions: human skin (pH 5.5), tumor microenvironment (pH 6.8), and bodily fluids (pH 7.4) [ 178 , 179 ]. Over 168 h, cumulative 2D5 release reached 68.3% at pH 5.5, 56.4% at pH 6.8, and 28.4% at pH 7.4. KPU, however, demonstrated a consistent release profile with 45.1%, 46.5%, and 44.9% at these pH levels. These results indicate that 2D5 exhibits pH-sensitive release, aligning with tumor environments, while KPU maintains steady dispersion, underscoring the hydrogel’s ability to modulate nanobody delivery based on pH variations and, therefore, its potential in targeted cancer therapy [ 177 ]. Calcium carbonate microspheres loaded with an iron and selenopeptide conjugate, incorporated into a human-like collagen scaffold, have been used to form a multifunctional collagen-based hydrogel designed for both skin filling and gastric cancer therapy. This collagen scaffold enabled precise and sustained delivery of the therapeutic iron and selenium conjugates directly to the tumor site, reducing systemic toxicity while promoting cancer cell death through apoptosis and ferroptosis mechanisms. The hydrogel’s integrated design combined the mechanical properties of calcium carbonate microspheres with the bioactivity of the conjugate and collagen’s natural compatibility, allowing effective localized skin regeneration and potent antitumor effects in gastric cancer treatment [ 180 ]. Moreover, such collagen-based hydrogels exhibited controlled degradation and responsive drug release, making them promising platforms for advanced, minimally invasive cancer therapies with improved therapeutic efficacy and reduced side effects compared to systemic chemotherapy [ 181 ]. Recent research has explored incorporating immune checkpoint inhibitors or immunostimulatory agents into hydrogels to suppress cancer metastasis [ 182 ]. Hwang et al. [ 183 ] developed a collagen-based thermosensitive hydrogel (pTRG) for immunotherapeutic agent delivery. The hydrogel was loaded with indocyanine green and polyinosinic:polycytidylic acid (poly I:C), an immune stimulator. Its therapeutic efficacy was evaluated in CT-26 carcinoma and 4T1 lung metastasis mouse models. When combined with photothermal therapy (PTT) and immunotherapy, pTRG promoted tumor-associated antigen expression, amplifying immune responses. Upon near-infrared irradiation at 808 nm, the hydrogel liquefied at 60 °C, ensuring controlled release of poly I:C, STING ligand, and immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies [ 184 ]. Drug quantification involved measuring differences between initially incorporated amounts and post-irradiation residuals. The hydrogel effectively eradicated CT-26 cancer cells in the lungs. Additionally, in re-challenge experiments with 4T1 cells, mice pre-treated with pTRG successfully resisted lung infiltration, whereas untreated mice exhibited metastasis. These findings highlight pTRG’s potential in integrating photothermal therapy with immunotherapy for breast cancer treatment [ 183 ]. 6.7. Elastin Elastin is a vital structural protein predominantly found in the ECM of various tissues, particularly within arterial walls, where it imparts elasticity and resilience, enabling blood vessels to withstand fluctuations in blood pressure. Beyond the vascular system, elastin is abundantly present in the lungs, skin, and ligaments, playing a fundamental role in maintaining tissue integrity and mechanical flexibility [ 185 ]. Elastin is primarily composed of tropoelastin monomers, which undergo extensive covalent cross-linking to form mature elastic fibers. This cross-linked network is responsible for elastin’s unique elastic properties and long-term durability in vivo [ 186 ]. Elastin fibers are typically associated with microfibrils, which act as a scaffold, further enhancing their mechanical stability and contributing to skin elasticity and resilience against mechanical deformation [ 187 ]. The development of elastin-like polymers (ELPs) and elastin-like recombinamers (ELRs), inspired by the repetitive motifs found in native elastin, represents a significant advancement in biomaterials science. These recombinant biopolymers, produced through genetic engineering techniques, closely replicate the physicochemical characteristics of natural elastin. Their biocompatibility and low immunogenicity render them highly suitable for biomedical applications, including drug delivery and tissue engineering [ 188 ]. A key feature of ELRs is their capacity for self-assembly, wherein individual polypeptide units autonomously organize into well-defined nanostructures, such as nanoparticles, hydrogels, and fibrous scaffolds. This self-assembling behavior is driven by reversible phase transitions in response to environmental stimuli, such as temperature, ionic strength, or pH [ 189 ]. Furthermore, ELPs and ELRs can be precisely engineered through genetic design, enabling control over their molecular weight, amino acid sequence, and structural properties. This molecular-level tunability facilitates the creation of monodisperse polymers with customizable pharmacokinetics and enhances the stability and solubility of therapeutic agents. These recombinant elastin-based materials can be functionalized with bioactive molecules, drugs, or targeting ligands, providing a versatile platform for the development of site-specific drug delivery systems [ 190 ]. In a recent study, ELR-based hydrogels have demonstrated significant potential in modulating post-ischemic remodeling in models of myocardial infarction (MI), particularly in non-transmural MI in sheep. Recent studies highlight that injectable, degradable ELR hydrogels, which mimic the native ECM, can reduce fibrosis, promote angiogenesis, and preserve cardiomyocyte integrity in the border zone of the infarcted tissue [ 191 ]. When applied in a clinically relevant ovine model, these hydrogels facilitated functional cardiac recovery by favorably influencing the ischemic environment, attenuating adverse remodeling, and fostering tissue regeneration. The elastic and biocompatible properties of ELR hydrogels enable them to integrate seamlessly into cardiac tissue, while their tunable degradation profiles allow controlled release of therapeutic agents and support tissue healing processes. Moreover, the ability of these hydrogels to mimic the ECM and exert mechanical stabilization within the infarcted myocardium underpins their effectiveness in improving cardiac function and preventing heart failure post-MI [ 192 ]. Their unique capacity to modulate cellular responses and remodeling pathways positions ELR hydrogels as promising candidates for regenerative therapy in post-ischemic cardiac repair [ 191 ]. The structural versatility and biological compatibility of elastin-derived materials position them as promising candidates for next-generation biomaterials in regenerative medicine, controlled drug delivery, and tissue remodeling applications [ 47 ]. Drug Delivery Applications and Cancer Treatment Elastin-derived materials have been investigated in various studies as innovative drug delivery platforms, including their application in the targeted delivery of salvianolic acid B for the treatment of MI [ 193 ]. Derived from elastin-mimetic peptides, this hydrogel combined natural elasticity, biocompatibility, and tissue-like mechanical resilience, enabling it to adapt to cardiac movement and maintain structural integrity after injection. The dynamic covalent or reversible physical interactions within the peptide network imparted self-healing behavior, allowing the hydrogel to recover from mechanical disruptions and ensure continuous drug release [ 194 ]. Salvianolic acid B, a potent antioxidant and cardioprotective compound, benefits from encapsulation in the elastin matrix, which provides localized and prolonged delivery to the infarcted region, enhancing myocardial repair, angiogenesis, and inhibition of oxidative stress. The hydrogel’s injectable nature facilitated minimally invasive administration, while its structural tunability allowed precise control over degradation rate and release kinetics, making elastin-based self-healing hydrogels a highly effective and biomimetic strategy for cardiac tissue regeneration and post-infarction drug therapy [ 193 ]. ELR hydrogels have emerged as promising biomimetic platforms for developing 3D breast cancer models. Blanco-Fernandez et al. [ 195 ] constructed ELR hydrogels using two distinct recombinant polypeptides, each composed of repeating pentapeptide sequences VPGXG (where V is valine, P is proline, G is glycine, and X is any amino acid other than proline). One ELR variant was engineered to incorporate matrix metalloproteinase (MMP)-sensitive domains, reflecting the proteolytic environment characteristic of breast tumors, along with cyclooctyne groups for click-chemistry crosslinking [ 196 , 197 ]. The second ELR was functionalized with arginylglycylaspartic acid (RGD) motifs to promote integrin-mediated cell adhesion, alongside azide groups enabling hydrogel formation through click-chemistry [ 198 ]. These ELR hydrogels closely mimic the ECM properties of breast tumors, offering a physiologically relevant microenvironment for in vitro cancer studies. The potential of these hydrogels was evaluated by encapsulating non-tumorigenic MCF10A cells, non-invasive MCF7 breast cancer cells, and invasive MDA-MB-231 breast cancer cells within the 3D hydrogel matrix. Upon exposure to various concentrations of the chemotherapeutic agent DOX, cells encapsulated within ELR hydrogels exhibited increased drug resistance compared to conventional 2D cultures, with the MCF7 cell line showing particularly pronounced resistance [ 199 ]. This observation underscores the capacity of ELR hydrogels to more accurately recapitulate the tumor microenvironment, thus providing a robust platform for assessing chemotherapeutic responses and enhancing the predictive value of preclinical cancer models [ 195 ]. Recent research highlights the potential of elastin-like polypeptide hydrogels in advancing cancer therapy through localized drug delivery. One notable study developed ELP hydrogels for tunable, sustained local chemotherapy in malignant glioma, demonstrating their capacity to release chemotherapeutic agents like DOX over extended periods, thereby enhancing treatment efficacy while minimizing systemic toxicity. The internal architecture of these ELP composites, as revealed by SEM analysis ( Figure 5 A), exhibited a highly defined scaffold morphology characterized by a porous network essential for controlled drug loading. These hydrogels were engineered for precise control over drug release profiles by manipulating polymer composition, making them suitable for post-surgical applications in glioma management. The biological performance of this system was further validated through co-localization studies using confocal microscopy. As shown in Figure 5 B, the treatment of U-87 MG cells with DOX-loaded ELP hydrogels resulted in a clear co-localization of the drug with the DAPI-stained nuclei. This qualitative visualization of nuclear and perinuclear fluorescence confirms the effective intracellular delivery and localization of doxorubicin, highlighting the potential of ELP hydrogels to serve as effective reservoirs for targeted chemotherapy in neuro-oncology [ 200 ]. In addition, another key investigation introduced an engineered elastin-like polypeptide-based hydrogel designed for co-delivery of chemotherapeutics and immune checkpoint inhibitors such as PD-L1 antibodies. This hydrogel depot facilitates in situ delivery, promoting a robust immune response, and significantly potentiates cancer immunotherapy by increasing tumor-infiltrating CD8 + T cells and depleting regulatory T cells (Tregs), thus improving overall treatment outcomes in melanoma and other tumor models [ 201 ]. Collectively, these elastin-based biomaterials demonstrate considerable potential as multifunctional platforms for localized, controlled, and sustained delivery of different biomolecules and anticancer agents. An overview of representative protein-based hydrogels and their applications is presented in Table 3 . 6.8. Peptide-Based Hydrogels In addition to full-length proteins, short peptide sequences have emerged as versatile building blocks for hydrogel design, offering highly tunable biochemical and mechanical properties. Their sequence-defined nature allows rational control over self-assembly, degradability, and interactions with therapeutic molecules or cancer cells. These features make peptide-integrated hydrogels particularly at
Recent Developments in Protein-Based Hydrogels for Advanced Drug Delivery Applications
蛋白质基水凝胶在先进药物递送应用中的最新研究进展
📄 中文摘要 Chinese Abstract
📋 英文结构化总结 English Structured Summary
全文整理
Background:
Protein-based hydrogels are increasingly recognized as promising biomaterials for advanced drug delivery due to their biocompatibility, biodegradability, and ability to mimic extracellular matrix (ECM)-like environments. These hydrogels can be engineered by tailoring protein sources, crosslinking strategies, molecular architecture, and functionalization to replicate the mechanical and biological features of native tissues. Natural proteins such as gelatin, collagen, silk fibroin, soy protein, casein, and whey protein are widely studied for forming hydrogels via physical, chemical, or enzymatic crosslinking, offering tunable mechanical behavior, controllable degradation, and efficient drug loading. Their responsiveness to stimuli like pH, temperature, or enzymatic activity enables precise control over drug release kinetics, making them attractive for targeted therapies, especially in cancer treatment. Despite their promise, challenges such as batch-to-batch variability, sterilization-induced denaturation, and incomplete long-term immunogenicity data hinder clinical translation.
Methods:
This review is based on a comprehensive literature search conducted using PubMed and Scopus databases, focusing on full-text, peer-reviewed research articles published between 2018 and 2025. The search terms included “hydrogel,” “protein,” “drug delivery system,” and “cancer treatment,” with queries adapted to each database. Extracted studies were systematically analyzed and categorized into thematic areas: hydrogel classification, physicochemical properties, synthesis techniques, drug delivery applications, and roles in cancer therapy. The review emphasizes natural protein-based hydrogels and evaluates their design principles, modification strategies, and biomedical relevance.
Results:
Protein-based hydrogels demonstrate significant potential as versatile platforms for controlled and stimuli-responsive drug delivery. They protect therapeutic molecules during transit—especially in harsh gastrointestinal environments—through pH-dependent conformational collapse near the isoelectric point, which reduces mesh size and shields cargo from enzymatic degradation. Upon reaching neutral pH regions (e.g., intestines), hydrogels re-expand, enabling site-specific release. Key release mechanisms include passive diffusion, stimuli-responsive swelling (e.g., in acidic tumor microenvironments), enzyme-triggered degradation by tumor-associated proteases, and cleavage of drug–protein conjugates under specific biochemical triggers. Gelatin-based hydrogels have been engineered for oral delivery of oxaliplatin with pH-sensitive swelling and sustained release in colorectal cancer models, while silk fibroin hydrogels offer tunable mechanical strength and drug-binding capabilities through β-sheet crystallization. Binary protein systems (e.g., soy-whey or zein-casein) show enhanced stability and rheological properties, supporting nanohydrogel formation with excellent redispersibility and prolonged shelf life.
Data Summary:
Studies report that calcium ion concentration significantly affects soy protein gel elasticity, with optimal stiffness at 7.5 mM Ca²⁺ but structural weakening at 10 mM. Zein forms stable dispersion gels at 15–20% (w/v) concentrations, exhibiting pseudoplastic behavior. Caseinate hydrogels crosslinked with transglutaminase at pH 5.7 show good water-holding capacity. In gelatin–guar gum systems, increasing gelatin content modulates gelation rate, porosity, and degradation. Doxorubicin-loaded gelatin methacrylate hydrogels exhibit sustained release over one month, with strong antiproliferative effects against HT-29 colon cancer cells. Oxaliplatin-loaded acrylic acid/AMPS-modified gelatin hydrogels demonstrate dose-dependent cytotoxicity against MCF-7 and HCT116 cell lines and oral tolerability in vivo. Silk fibroin hydrogels crosslinked with horseradish peroxidase show increased stiffness, resilience, and β-sheet content. Binary soy-wheat protein gels heated to 95 °C form stronger networks when whey protein dominates, with soy acting as a filler enhancing elasticity via hydrophobic interactions.
Conclusions:
Protein-based hydrogels represent a powerful class of biomaterials that bridge natural bioactivity with synthetic tunability, enabling next-generation drug delivery systems. Their inherent biocompatibility, biodegradability, and capacity for stimuli-responsive behavior make them ideal for localized, sustained, and targeted therapy—particularly in cancer treatment. Advances in crosslinking methods (physical, chemical, enzymatic) and hybrid designs allow precise control over mechanical properties, degradation rates, and release kinetics. However, clinical translation requires addressing critical limitations including batch variability, sterilization sensitivity, and insufficient long-term immunogenicity profiling. Future research must focus on engineering spatiotemporally controlled release systems, understanding protein conformation and release mechanisms, and ensuring biocompatibility beyond cytotoxicity to include immune response and tissue remodeling.
Practical Significance:
Protein-based hydrogels hold substantial real-world potential for developing oral, injectable, and implantable drug delivery systems that improve therapeutic efficacy while minimizing systemic toxicity. Their ability to protect labile drugs in the gastrointestinal tract and release them selectively in target tissues—such as tumors—enables safer, more effective treatments for diseases like colorectal cancer. Additionally, their intrinsic antibacterial properties and support for tissue regeneration expand applications to wound healing, dermatitis, and regenerative medicine, positioning them as multifunctional platforms for precision medicine and personalized therapy.
📋 中文结构化总结 Chinese Structured Summary
背景:
蛋白质基水凝胶因其良好的生物相容性、生物可降解性以及模拟细胞外基质(ECM)样环境的能力,被越来越多地认为是先进药物递送领域极具前景的生物材料。这些水凝胶可通过调控蛋白质来源、交联策略、分子结构和功能化修饰来模拟天然组织的力学和生物学特性。明胶、胶原蛋白、丝素蛋白、大豆蛋白、酪蛋白和乳清蛋白等天然蛋白质被广泛研究,可通过物理、化学或酶法交联形成水凝胶,具有可调的力学性能、可控的降解特性和高效的药物负载能力。它们对pH、温度或酶活性等刺激的响应性使其能够精确控制药物释放动力学,因此在靶向治疗(尤其是癌症治疗)中具有吸引力。尽管前景广阔,但批次间差异、灭菌引起的变性以及长期免疫原性数据不完整等挑战阻碍了其临床转化。
方法:
本综述基于PubMed和Scopus数据库进行的系统性文献检索,重点纳入2018年至2025年间发表的同行评审全文研究文章。检索词包括"hydrogel"(水凝胶)、"protein"(蛋白质)、"drug delivery system"(药物递送系统)和"cancer treatment"(癌症治疗),并根据各数据库特点调整检索策略。提取的研究被系统分析并归类为以下主题领域:水凝胶分类、理化性质、合成技术、药物递送应用以及在癌症治疗中的作用。本综述重点聚焦天然蛋白质基水凝胶,评估其设计原理、修饰策略和生物医学相关性。
结果:
蛋白质基水凝胶作为可控和刺激响应型药物递送的多功能平台展现出巨大潜力。它们通过等电点附近的pH依赖性构象塌缩来保护治疗分子在转运过程中(尤其是在恶劣的胃肠道环境中)免受破坏,这种塌缩减小了网格尺寸并保护药物免受酶降解。当到达中性pH区域(如肠道)时,水凝胶重新膨胀,实现位点特异性释放。主要释放机制包括被动扩散、刺激响应性肿胀(如在酸性肿瘤微环境中)、肿瘤相关蛋白酶触发的酶降解,以及特定生化触发下药物-蛋白偶联物的裂解。明胶基水凝胶已被设计用于奥沙利铂的口服递送,在结直肠癌模型中表现出pH敏感肿胀和持续释放特性;丝素蛋白水凝胶则通过β-折叠结晶提供可调的力学强度和药物结合能力。二元蛋白体系(如大豆-乳清或玉米醇溶蛋白-酪蛋白)表现出增强的稳定性和流变性能,支持纳米水凝胶的形成,具有优异的分散再溶性和延长的保质期。
数据汇总:
研究表明,钙离子浓度显著影响大豆蛋白凝胶的弹性,在7.5 mM Ca²⁺时达到最佳刚度,但在10 mM时结构减弱。玉米醇溶蛋白在15-20%(w/v)浓度下形成稳定的分散凝胶,表现出假塑性行为。在pH 5.7条件下经转谷氨酰胺酶交联的酪蛋白酸盐水凝胶具有良好的持水能力。在明胶-瓜尔胶体系中,增加明胶含量可调节凝胶化速率、孔隙率和降解性能。负载阿霉素的甲基丙烯酰化明胶水凝胶在一个月内表现出持续释放,并对HT-29结肠癌细胞具有显著的抗增殖效果。负载奥沙利铂的丙烯酸/AMPS改性明胶水凝胶对MCF-7和HCT116细胞系表现出剂量依赖性的细胞毒性,并在体内显示出口服耐受性。经辣根过氧化物酶交联的丝素蛋白水凝胶表现出更高的刚度、回弹性和β-折叠含量。加热至95°C的大豆-小麦蛋白二元凝胶在乳清蛋白占主导时形成更强的网络结构,大豆蛋白作为填充剂通过疏水性相互作用增强弹性。
结论:
蛋白质基水凝胶代表了一类强大的生物材料,将天然生物活性与可调控性相结合,能够实现新一代药物递送系统。其固有的生物相容性、生物可降解性和刺激响应行为使其成为局部、持续和靶向治疗(尤其是癌症治疗)的理想选择。交联方法(物理、化学、酶法)和杂化设计的进步使得对力学性能、降解速率和释放动力学的精确控制成为可能。然而,临床转化仍需解决批次差异、灭菌敏感性以及长期免疫原性评估不足等关键局限性。未来研究应聚焦于工程化时空可控释放系统、深入理解蛋白质构象与释放机制,并确保超越细胞毒性的生物相容性评估,包括免疫反应和组织重塑。
实践意义:
蛋白质基水凝胶在开发口服、注射和植入式药物递送系统方面具有巨大的现实潜力,可提高治疗效果同时最小化全身毒性。它们能够保护不稳定药物在胃肠道中的完整性,并在靶组织(如肿瘤)中选择性释放,从而为结直肠癌等疾病提供更安全、更有效的治疗。此外,其固有的抗菌特性和对组织再生能力的支持拓展了其在伤口愈合、皮炎和再生医学中的应用,使其成为精准医学和个性化治疗的多功能平台。
📖 英文全文 English Full Text
📖 中文全文 Chinese Full Text
以下是该学术段落的中文翻译,严格保留技术术语的准确性:
---
**基于蛋白质的水凝胶在先进药物递送应用中的最新进展**
蛋白质基水凝胶因其良好的生物相容性、生物可降解性以及模拟细胞外基质样环境的能力,日益被视为先进药物递送领域极具前景的生物材料。通过调控蛋白质来源、交联策略、分子结构及其功能化修饰,这些水凝胶可被设计为模拟天然组织的力学与生物学特性。目前,蛋白质衍生水凝胶在生物医学与制药领域得到广泛探索,包括药物递送系统、伤口愈合、组织工程以及癌症治疗等方向。近年来,天然蛋白质水凝胶因其固有的生物活性与多样的理化性质而受到越来越多的关注。本文综述了基于蛋白质的水凝胶的分类、性质与制备方法,重点介绍了明胶、胶原蛋白、丝素蛋白、大豆蛋白、酪蛋白和乳清蛋白等广泛研究的天然蛋白质,它们可通过物理、化学或酶促交联形成水凝胶。这些材料具有可调的力学性能、可控的降解速率以及丰富的官能团,有利于高效载药及刺激响应型平台的构建。此外,本文还综述了其在药物递送系统中的最新应用进展,尤其聚焦于癌症治疗。研究表明,蛋白质基水凝胶能够保护治疗分子、实现持续或靶向释放,并增强治疗效果。尽管在从临床前研究向临床转化过程中仍面临批次间差异、灭菌引起的变性以及长期免疫原性评估不足等关键挑战,但天然蛋白质水凝胶在设计与功能化方面的持续进展,凸显了其作为下一代精准药物递送平台的巨大潜力。
---
**1. 引言**
聚合物水凝胶是三维(3D)交联网络结构,能够吸收大量水分和生物液体,同时保持结构完整性。其高弹性和高含水量赋予其类似组织的力学性能和优异的生物相容性,使其非常适用于生物医学应用。多年来,水凝胶因其可调的化学组成和多孔结构,已被广泛应用于药物递送、组织工程、伤口愈合和癌症治疗等领域,这些特性使其能够包埋并控制释放治疗药物。水凝胶可分为常规型与刺激响应型(“智能型”)两类。常规水凝胶通常仅通过简单的溶胀或去溶胀行为响应pH或温度等环境变化,且常存在力学性能较差的问题。相比之下,智能水凝胶被设计为在pH、温度、离子强度、光或磁场等刺激下发生显著的物理化学变化。这种响应行为可实现对药物释放动力学、定位和时机的精确控制,使其在按需治疗和精准医学中极具吸引力。在众多水凝胶体系中,蛋白质基水凝胶因其固有的生物相容性、生物可降解性和生物学功能而脱颖而出,成为极具前景的生物材料。这类水凝胶来源于天然或重组蛋白,如胶原蛋白、明胶、丝素蛋白、白蛋白和丝胶蛋白,能够高度模拟细胞外基质(ECM),促进细胞黏附、增殖和分化。其力学与生化可调性使其既能作为组织再生的支架,又能作为局部持续药物递送的载体。与合成聚合物网络相比,蛋白质基水凝胶具有多项优势:其天然来源确保了低免疫原性与良好的生物组织整合性;其分子结构可通过化学交联、酶促反应或基因工程进行修饰,从而构建响应pH、温度或酶活性的刺激响应型系统。此类“智能”蛋白质水凝胶已在癌症治疗中用于局部药物递送,减少脱靶毒性并提高治疗效果。在伤口愈合应用中,蛋白质基水凝胶提供湿润、富含生物活性的环境,支持血管生成并加速组织修复,尤其在负载生长因子或抗菌剂时效果更佳。在药物递送方面,它们可在维持治疗分子生物活性的同时实现可控、长效释放,并最小化全身副作用。纳米技术与杂化材料设计的进步进一步提升了其稳定性和机械强度,拓展了其在再生医学、癌症免疫治疗和靶向联合疗法中的应用。鉴于上述进展,蛋白质基水凝胶代表了一类兼具天然与合成系统优势的通用且强大的生物材料。其可调性、多功能性和生物相容性使其成为下一代治疗平台的理想候选者。本综述探讨了天然蛋白质基水凝胶的设计原理、修饰策略及生物医学应用,重点聚焦于其在药物递送和癌症治疗中的作用。
---
**2. 材料与方法**
本研究以PubMed和Scopus为主要数据库进行了系统性文献综述。检索限定为英文全文同行评议研究论文,聚焦于蛋白质基水凝胶在药物递送系统中的应用。为确保相关性,仅纳入2018年至2025年间发表的研究。检索策略采用特定关键词,包括“hydrogel”、“protein”、“drug delivery system”和“cancer treatment”,并根据各数据库特点调整检索式。对相关研究进行系统分析,提取数据并按水凝胶分类、理化性质、合成技术、药物递送应用及癌症治疗作用等关键主题进行分类。
---
**3. 天然聚合物基水凝胶**
天然来源的水凝胶因其固有的生物功能性,日益被视为制药、生物医学和癌症治疗领域最具前景的材料。在制药应用中,天然水凝胶作为智能药物递送平台,能够包埋生物活性分子并实现可控、持续释放,从而提高药物生物利用度并降低全身毒性。在生物医学领域,其仿生特性支持细胞黏附、增殖和分化,对伤口愈合、组织工程和再生医学至关重要。此外,其可调的溶胀行为、生物降解性及温和的凝胶化条件,使其能够在不损失活性的前提下包埋蛋白质、生长因子和核酸等敏感生物分子。在癌症治疗中,它们在局部刺激响应型药物递送、肿瘤靶向和免疫调节方面发挥着日益重要的作用。其生物相容性和对环境信号的响应能力,使其能够在肿瘤微环境中精准、局部地释放化疗或免疫治疗药物,从而增强疗效、减少全身副作用,并可通过整合生物活性天然成分进一步促进组织再生和免疫调节。尽管天然水凝胶具有显著优势,但其机械稳定性、长期耐久性和批次间重复性仍存在局限。为解决这些问题,有时采用合成水凝胶,如聚乙二醇(PEG)、聚乙烯醇(PVA)或聚丙烯酰胺(PAAm)基水凝胶,因其结构精确、性能可调且机械强度高。然而,合成系统通常缺乏固有生物活性,需通过化学修饰或与天然聚合物共混以改善细胞识别和生物相容性。在此背景下,天然与合成聚合物结合的杂化水凝胶应运而生,整合了天然材料的生物学优势与合成材料的机械强度与可调性。例如,羧甲基纤维素(CMC)-PEG和海藻酸盐-PVA杂化水凝胶表现出增强的结构稳定性、可控的降解行为和更高的药物包埋效率,同时保留了细胞相容性和生物功能性。尽管合成与杂化系统有助于克服部分实际限制,但天然来源的材料仍在持续启发新一代生物活性水凝胶的设计,使其能够模拟天然组织,并在药物递送、组织工程和癌症治疗中实现先进治疗应用。
天然来源的生物聚合物可根据其结构组成和功能特性分为三大类(图1)。第一类为多糖,包括壳聚糖、透明质酸和海藻酸盐,因其良好的生物相容性、生物降解性和成胶能力而被广泛使用。第二类为蛋白质基生物聚合物,如明胶、胶原蛋白、丝素蛋白和基于肽的系统,具有优异的机械强度和生物活性,适用于生物医学和制药应用。第三类为核酸,如DNA基水凝胶,是一类新兴的生物聚合物,具有独特的自组装特性,在基因递送、组织工程和生物传感方面具有潜在应用价值。
---
**4. 蛋白质基水凝胶**
在常用于水凝胶形成的天然生物聚合物中,明胶、胶原蛋白和丝素蛋白因其优异的成胶性能而备受关注。明胶来源于胶原蛋白的部分水解,富含细胞结合RGD序列,可增强生物活性和细胞黏附。胶原蛋白作为细胞外基质的主要成分,提供结构完整性和细胞相互作用及组织支持所必需的生物信号。丝素蛋白(SF)具有可调的凝胶化动力学、机械强度和生物相容性,但可能缺乏内在的细胞黏附基序,可通过与明胶复合来补充。这些蛋白质可通过酶促、化学或物理交联形成水凝胶,从而实现对力学性能、溶胀行为和生物降解性的调控。此类水凝胶因其仿生环境和适宜的机械特性支持细胞生长增殖,并能包埋敏感生物分子。交联技术的进步有助于克服生理条件下热稳定性差和快速降解等挑战,促进稳定且功能化的蛋白质基水凝胶的开发。
基于上述进展,多种天然蛋白质被探索作为水凝胶形成的结构组分,每种蛋白质具有不同的凝胶化机制和功能特性。例如,Wang等人利用大豆分离蛋白通过盐离子诱导法制备乳液凝胶。添加Ca²⁺(0–7.5 mM)显著提高了凝胶的弹性,形成更坚硬且持水能力更强的结构。有趣的是,当钙浓度达到10 mM时,凝胶反而变弱,呈现疏松、不均匀的结构。Gagliardi等人研究了玉米醇溶蛋白基水凝胶的特性,发现其在15%和20%(w/v)浓度下可形成稳定的分散凝胶。此外,高玉米醇溶蛋白含量促进了假塑性行为,为食品生产提供了一种有前景的低成本配方。De Kruif等人使用酪蛋白酸钠(15%,w/w)和转谷氨酰胺酶(TGase)交联剂在pH 5.7条件下制备了透明凝胶。所得酪蛋白水凝胶具有良好的持水能力。除上述系统外,其他蛋白质如胶原蛋白、β-乳球蛋白、α-乳白蛋白、牛血清白蛋白(BSA)、豌豆蛋白和乳铁蛋白也被用于开发单蛋白质水凝胶。这些材料根据其氨基酸组成和分子构象表现出多样的结构和功能特性,从而可精确调控凝胶强度、孔隙率和生物降解性。
蛋白质基水凝胶设计中的一个基本考量是蛋白质来源的选择,这决定了材料的生物活性、成本和监管路径。天然蛋白质大致可分为动物源和植物源两类,各自在临床转化方面存在不同的权衡。动物蛋白如胶原蛋白和明胶具有优异的仿生特性和固有的细胞信号基序(如RGD序列),但常面临显著的批次间差异和潜在的人畜共患病风险。相比之下,植物源蛋白如大豆蛋白和玉米醇溶蛋白提供了更具可持续性和成本效益的替代方案,具有更高的重复性和更低的免疫原性。然而,植物来源通常缺乏动物细胞外基质中固有的生物“信号”,常需通过化学功能化或与合成聚合物杂化,以实现先进治疗应用所需的机械强度和细胞识别能力。这两类生物来源在临床可转化性、重复性和固有生物活性方面的主要权衡总结于表1。
尽管对蛋白质分子间相互作用的研究已较为充分,但双蛋白质水凝胶仍是一个相对新兴的研究领域。McCann等人研究了大豆蛋白-乳清蛋白双蛋白质水凝胶的结构和流变特性。加热至95°C时,乳清蛋白在复合凝胶中形成主要网络结构,随着乳清蛋白浓度降低,凝胶强度减弱。大豆蛋白作为填充剂,大豆蛋白与乳清蛋白之间的疏水性相互作用增强了凝胶的弹性性能。此外,Pan和Zhong通过玉米醇溶蛋白与酪蛋白的共组装开发了稳定的纳米水凝胶。将玉米醇溶蛋白与酪蛋白酸钠在pH 11.5混合后,调节pH至7.0实现共组装,形成直径小于100 nm的球形水凝胶纳米颗粒。这些纳米水凝胶在4°C下可稳定保存30天,冻干后的纳米颗粒表现出优异的分散性。Sarbon等人研究了明胶-乳清蛋白双凝胶的微观结构、热学和流变特性。当与明胶(3%、5%和10%)复合时,复合水凝胶的弹性模量显著高于单独的10%乳清蛋白凝胶。这可能是由于两种蛋白质之间的协同分子间相互作用。凝胶强度、结构完整性和热稳定性也随明胶浓度增加而提高。在低浓度下,明胶填充了乳清蛋白凝胶的网络空间;而在高浓度下,则诱导形成连续的凝胶网络。
蛋白质的另一显著优势在于其结构和功能的多样性,使其能够实现精确的药物靶向。其固有的结合位点使药物能够与靶分子特异性相互作用,同时可将多种靶向配体偶联至蛋白质基纳米载体,进一步增强位点特异性递送。这种多功能性使蛋白质纳米颗粒成为可控药物递送和组织工程应用的高效平台。
尽管水凝胶基递送系统具有广阔前景,但其临床转化仍面临若干关键限制。最紧迫的挑战包括组织整合的异质性、水凝胶界面处的细胞脱落倾向以及包埋蛋白质的不稳定性或过早降解。这些问题可能严重影响递送平台的治疗效能和重复性,限制其在再生医学和其他生物医学领域的应用。为将临床前成功有效转化为有意义的临床成果,未来研究应优先开发更稳健、可调的蛋白质释放系统。这包括设计具有时空可控释放曲线的水凝胶,使其能够适应特定生物信号和组织微环境。此外,深入理解蛋白质构象、蛋白质基水凝胶内的分子相互作用以及释放动力学机制至关重要。这些见解对于优化生物活性保持和确保在治疗相关浓度下的持续递送不可或缺。同样重要的是,生物相容性的评估不仅应考虑细胞毒性,还应涵盖免疫反应、降解产物和长期组织重塑。通过应对这些多维挑战,下一代蛋白质基水凝胶可被合理设计,以实现可预测、安全有效的体内 outcomes。
---
**5. 合成方法**
蛋白质基水凝胶因其三维网络结构而被广泛认可,可通过多种策略合成,这些策略利用蛋白质单体与超分子组装体之间的共价和非共价相互作用。根据合成方法的不同,所得水凝胶可表现出不同的结构、机械和功能特性,使其高度可调,适用于特定生物医学应用。这些技术包括物理交联、化学交联、酶促过程和自组装方法。这些合成策略可实现对蛋白质基水凝胶物理、化学和机械性能的精确控制(图2)。以下各节将详细综述这些技术,重点介绍其在药物递送、组织工程和其他生物医学应用中的代表性实例和意义。
**5.1. 物理合成方法**
通过物理方法形成蛋白质水凝胶依赖于弱分子相互作用,包括静电作用、氢键和疏水相互作用。这些方法避免使用化学交联剂,保留了蛋白质聚合物的生物相容性和功能性。例如,明胶或胶原蛋白等蛋白质的羧基与其他聚合物之间的氢键可形成具有可调力学性能的pH响应性凝胶。Sun等人研究了带相反电荷的肽残基之间的电荷分布和离子互补性如何驱动β-纳米纤维的侧向关联,形成纳米纤维、束和纳米片等纳米结构。这些组装体通过静电和离子相互作用形成物理交联网络,从而调控水凝胶的黏弹性及其从黏性态到自支撑态的转变。通过调节肽电荷模式、离子强度和多价反离子,可精确控制物理交联密度和稳定性,为生物工程和生物材料应用提供无需化学交联剂的生物相容性水凝胶。这些物理合成方法在生物医学应用中具有显著优势,可开发适用于药物递送和组织工程的可注射、自修复水凝胶。
**5.1.1. pH诱导法**
除静电相互作用外,pH还可诱导物理交联,有助于水凝胶网络的形成和稳定。通过精细调节pH,可调控蛋白质的溶解度、电荷分布和构象状态,从而促进可控聚集和水凝胶形成。例如,在酸性pH(约pH 3.5)下,BSA采取F型(部分膨胀的雪茄状)构象,促进聚集和凝胶化。这种构象变化由静电排斥驱动,导致部分变性并暴露疏水核心区域,尽管仍存在静电排斥,这些区域对蛋白质聚集至关重要。BSA在此F型构象下的凝胶化可在室温下24小时内发生,或在37°C下更快。相反,在碱性条件下,BSA经历不同的构象重排,促进荧光水凝胶的形成。这些结构具有自修复和多功能特性,适用于生物传感和成像应用。这种pH驱动方法不仅限于BSA。类似策略已成功应用于其他蛋白质系统。例如,弹性蛋白原(tropoelastin)是弹性蛋白的可溶性前体,是人体关键结构蛋白,在暴露于pH > 10的碱性条件时,采取独特的α-螺旋、聚脯氨酸II型样构象。这种结构转变由静电相互作用和氢键模式的变化驱动,促进疏水结构域的排列,并随后自组装成弹性蛋白样纤维网络。这种pH诱导的构象重排对于调控弹性蛋白基水凝胶的材料特性(包括弹性、稳定性和仿生应用能力)至关重要。
**5.1.2. 金属离子诱导合成**
金属离子在蛋白质水凝胶形成中充当交联剂。某些重组蛋白在光照下与金属离子相互作用,使可注射、光响应性水凝胶的开发成为可能。金属离子能够诱导乳清蛋白纳米纤维的交联,将溶液转化为水凝胶。高价离子(Al³⁺、Sn⁴⁺)在较低浓度下即可形成凝胶,而单价离子(Na⁺、K⁺)则需要更高浓度。此外,多价离子如Fe³⁺或Co²⁺可增强水凝胶的机械强度,支持其在生物医学中的应用。乳清蛋白,特别是β-乳球蛋白,在预变性并暴露于二价金属离子(如Fe²⁺)时,可通过冷凝胶化形成稳定的水凝胶。金属离子作为交联剂,促进聚集和网络形成,凝胶结构和稳定性强烈依赖于离子浓度和蛋白质的预聚集状态。此外,在热变性过程中施加中等电场可调节蛋白质聚集,从而更精细地调控水凝胶的微观结构和机械性能,进而提升其功能和营养性能。
**5.1.3. 温度诱导合成**
热加工是水凝胶形成的另一种有效方法。例如,乳清蛋白基水凝胶与莲藕支链淀粉结合并在95°C加热时,由于加热诱导的相互作用和结构变化改善了凝胶形成,表现出增强的机械稳定性。冷固化水凝胶则是在低温下形成的。这种方法广泛用于可控药物释放应用,因为它允许在不降解的情况下包埋温度敏感的生物活性化合物。例如,由葡萄糖酸-δ-内酯和氯化钠等添加剂诱导的冷固化凝胶用于包埋并控制释放药物。热处理形成的蛋白质聚集体,如淀粉样纤维和链,可在室温下通过改变pH或盐浓度进一步调控,形成冷固化凝胶。与热固化凝胶相比,这些冷固化凝胶通常具有更优的机械性能、更高的吸水性和更低的凝胶化浓度。此类凝胶特别适用于固定带电生物活性物质,实现靶向和可控释放。
**5.2. 化学合成方法**
化学交联策略在蛋白质分子间建立强共价键,产生稳定性增强的水凝胶。化学交联剂分为非零长度型(连接相邻多肽,如戊二醛(GLU)、聚环氧化物)和零长度型(在邻近反应基团间形成直接共价键,如1-乙基-3-(3-二甲氨基丙基)-碳二亚胺(EDC))。Wang等人通过热-酸法制备乳清蛋白分离物纤维,随后使用柠檬酸(CA)交联形成具有可调黏弹性的冷固化水凝胶。CA作为化学交联剂,根据pH和浓度诱导从溶液或软凝胶态向刚性凝胶态的相变。在酸性条件(pH 2)下,400 mmol/L CA时凝胶化最佳;在中性和碱性条件(pH 7–10)下,100 mmol/L CA时凝胶化最佳。CA添加后储能模量(G')的增强表明其通过pH依赖性相互作用和电荷调控促进乳清蛋白分离物纤维的分子间交联,形成稳定的自支撑水凝胶,发挥了关键作用。在另一项研究中,使用GLU和甘油醛(GAL)对明胶水凝胶进行化学交联,以研究交联剂类型、浓度和溶剂组成对网络形成和稳定性的影响。GLU在所有测试条件下均高效产生稳定、高交联的水凝胶,而GAL则需要更高浓度的丙酮水平,可能是由于丙酮的脱水效应增强了GAL与明胶胺席夫碱形成的反应性。
**5.3. 酶诱导合成**
酶促交联是一种仿生方法,利用酶催化蛋白质分子间共价键的形成,用于构建蛋白质基水凝胶。与传统化学交联相比,该方法具有反应条件温和、生物相容性增强等优势。此外,酶可靶向蛋白质中的特定氨基酸残基,实现更可控、位点特异的交联,从而改善机械性能并促进功能化。常用的酶包括TGase、酪氨酸酶和辣根过氧化物酶(HRP),它们通过不同的氨基酸侧链催化交联。Sahoo等人全面研究了如何利用HRP介导的交联通过调控丝素蛋白提取条件来调节和增强SF水凝胶的机械性能。他们的研究提供了HRP催化二酪氨酸交联的直接证据,力学表征显示HRP交联的丝素水凝胶的刚度、回弹性和β-折叠含量显著增加。关于负载生物活性颗粒的磷酸肌酸接枝明胶水凝胶的研究强调了酶催化蛋白质水凝胶作为多功能支架的潜力,通过精确的生化与结构调控促进协同组织再生。TGase介导的交联增强了支架的结构和功能特性,促进了温和高效的共价键合,并允许整合层级结构的特立帕肽/锶-锌磷酸盐功能化的Zn-Cu颗粒,而不影响生物活性。这些研究实例展示了酶介导交联作为开发先进蛋白质水凝胶的生物相容性策略在生物医学应用中的优势。
广泛的合成方法为精细调控蛋白质基水凝胶的性能提供了可能,使其高度适应于生物医学、药物递送和生物材料科学等多种应用。
---
**6. 用于药物递送的蛋白质基水凝胶**
蛋白质基水凝胶因其固有的生物相容性、可调的生物降解性以及形成高度水化三维网络的能力,已成为极具通用性的药物递送平台。其天然来源提供了固有的生物活性和结构基序,有利于与治疗分子发生有利相互作用,同时其对pH、温度或酶活性等环境信号的响应性,使其能够实现可控和刺激响应型释放曲线。此外,蛋白质中丰富的化学官能团允许采用多种交联策略,促进具有定制力学性能、稳定性和载药水凝胶的设计。如图3所示,蛋白质基水凝胶通过在单一材料系统中整合多种释放机制,提供了高度通用且精确可控的治疗递送平台。最基本的释放模式是通过被动扩散(图3A),其中药物分子沿浓度梯度从水凝胶基质迁移至周围组织。该机制主要由蛋白质网络的网格尺寸、治疗剂的分子量和水凝胶的交联程度决定。除简单扩散外,“智能”蛋白质水凝胶常被设计为对病理信号动态响应。刺激响应性溶胀(图3B)使水凝胶能够响应pH等环境条件发生可逆体积变化。在癌症治疗中,暴露于酸性肿瘤微环境可诱导水凝胶膨胀,增加网格渗透性,从而以空间选择性的方式加速药物释放。蛋白质基水凝胶由于其肽主链而具有固有的生物降解性,可用于酶触发释放(图3C)。肿瘤相关蛋白酶(常由恶性细胞过表达)可选择性地切割水凝胶支架内的肽序列。这种酶促侵蚀逐渐破坏基质结构,实现包埋治疗载荷的持续局部释放,同时最小化脱靶暴露。除物理包埋外,治疗剂可通过可裂解连接子化学偶联至蛋白质网络(图3D)。这些药物-蛋白质偶联物在循环中保持稳定,但在暴露于病变组织中存在的特定化学、酶或氧化还原触发物时解离。该策略提供了额外的控制层,确保药物激活和释放仅在明确的生物学条件下发生,从而增强治疗效果并降低全身毒性。
除可调的合成与释放特性外,蛋白质基水凝胶在保护包埋治疗剂通过恶劣生理环境(特别是口服递送)方面发挥关键作用,否则不稳定的生物制剂会在胃部条件下迅速降解。这种保护功能在口服和黏膜递送途径中尤为重要,因为在这些途径中,药物在到达作用位点前会暴露于极端pH、消化酶和机械应力。这种保护的关键机制是蛋白质网络的pH依赖性构象行为。暴露于酸性环境(如胃部,pH 1.2–2.0)时,由于接近许多蛋白质的等电点(pI),水凝胶会发生显著的结构塌缩。在pI下,蛋白质链间的静电排斥最小化,导致网络致密化和网格尺寸显著减小。这种构象塌缩产生显著的位阻效应,有效形成物理屏障,限制蛋白酶(包括胃蛋白酶)的扩散和渗透,从而保护包埋的治疗载荷免受过早降解。同时,蛋白质基水凝胶由于其结构中高密度可电离氨基酸侧链而具有内在缓冲能力。这些官能团部分中和周围的酸性介质,在凝胶核心内形成比整体胃液酸性更低的局部微环境。这种缓冲效应进一步有助于保持pH敏感化合物(包括脆弱的肽、蛋白质和疏水性小分子)的结构完整性和生物活性。重要的是,这种保护性屏蔽是可逆的:当环境转变为接近中性的pH(如小肠)时,蛋白质链间的静电排斥恢复,促进水凝胶再膨胀和网络渗透性增加。这种pH触发的溶胀使得治疗载荷能够通过扩散、酶促侵蚀或药物-蛋白质不稳定连接子的切割实现可控、位点特异性释放。综上所述,这些机制凸显了蛋白质基水凝胶不仅作为递送基质,更作为活性保护载体,确保药物在转运过程中的稳定性并增强治疗效果。
表2总结了常用于水凝胶制备的蛋白质来源,重点介绍了它们在药物递送中的主要特性、交联方法和治疗相关性。下一节将讨论几种代表性蛋白质的特性,并介绍其作为药物递送系统应用的实例,尤其聚焦于癌症治疗策略。
**6.1. 明胶**
明胶是通过动物胶原蛋白酸水解获得的变性蛋白。这种生物分子多年来在制药、化妆品和食品工业中广泛应用。明胶的显著效应之一是其变性过程能够刺激免疫系统。明胶作为聚两性电解质,具有平衡比例的阳离子和阴离子活性基团以及疏水基团,比例为1:1:1。这导致明胶分子具有约13%的正电荷(来自赖氨酸和精氨酸等氨基酸)、12%的负电荷(来自谷氨酸和天冬氨酸)和11%的疏水氨基酸(包括亮氨酸、异亮氨酸、甲硫氨酸和缬氨酸)。其余结构主要由甘氨酸、脯氨酸和羟脯氨酸组成。阳离子明胶来源于1型猪皮肤胶原蛋白的酸水解,而阴离子明胶则通过牛胶原蛋白水解获得。明胶用于多种全身用药物制剂,临床上作为血浆扩容剂以及蛋白质制剂、疫苗和明胶基海绵(如明胶海绵)中的稳定剂。
精氨酸-赖氨酸-甘氨酸序列在多种细胞外基质蛋白中至关重要,通过与细胞表面整合素受体的β亚基相互作用促进细胞结合和通讯。这一特性使明胶相较于常缺乏特异性细胞识别和结合位点的合成聚合物具有显著优势。此外,明胶内的活性基团允许通过不同连接子进行多种化学修饰,这对于开发靶向药物递送系统以及将大量药物连接至载体具有重要价值。
在其各种形式中,明胶水凝胶因其卓越的保水性和黏弹性而充当有效的持续释放载体。它可在特定压力条件下吸收水分并在脱水后再溶胀。当前研究表明,明胶水凝胶可通过多种方法合成,包括化学交联、温度诱导交联、光交联和酶介导交联。然而,通过温度和光交联制备的水凝胶性能常因环境条件变化而不够理想。
**药物递送应用与癌症治疗**
由于其固有的生物相容性和形成稳定三维网络的能力,明胶基水凝胶代表了先进药物递送系统的一类有前景的材料。最近,开发了一种苯硼酸修饰的甲基丙烯酰化明胶水凝胶,用于在高活性氧(ROS)和低pH条件下释放表没食子儿茶素没食子酸酯(EGCG),以减轻椎间盘退变模型中的炎症。苯硼酸用于引入能实现UV交联和动态硼酸酯形成的官能团。所得水凝胶具有高溶胀能力、可调的机械强度和酶降解性,均为生物医学应用所必需,并在体内保护髓核细胞同时维持椎间盘结构。
除作为生物活性分子的优异载体外,明胶还表现出促进组织再生和愈合的固有生物活性。Canafístula等人通过将明胶与碳水化合物基聚合物瓜尔胶结合,利用明胶的天然生物相容性和亲水性以及氧化瓜尔胶通过席夫碱化学交联的机械强度和化学反应性,开发了一种创新的水凝胶系统。所得水凝胶表现出依赖于明胶含量的可调理化性质,包括凝胶化速率、交联密度、孔隙率和降解行为的变化。值得注意的是,明胶-瓜尔胶水凝胶对耐甲氧西林金黄色葡萄球菌(MRSA)和其他葡萄球菌菌株表现出强烈的内在抗菌活性,即使在未添加抗生素的情况下。此外,它们还表现出优异的细胞相容性、无刺激性以及理想的粘附性、可注射性和自修复等功能特性,凸显了其在伤口愈合、皮炎和眼科治疗等局部药物递送应用中的潜力。
在另一项研究中,通过原位多巴胺触发的反应在硫酸锌(ZnSO₄)存在下开发了多巴胺和[2-(甲基丙烯酰氧基)乙基]二甲基-(3-磺酸丙基)氢氧化铵(SBMA)修饰的明胶水凝胶。这种有机-无机双网络赋予了仿生粘附性、自修复能力和热稳定性。锌离子既作为交联剂又作为生物活性剂,促进持续的抗菌作用。明胶基质提供了生物相容性、亲水性且多孔的底物,适用于治疗分子或离子的可控释放。修饰后的明胶水凝胶对大肠杆菌和金黄色葡萄球菌表现出完全(高达100%)的抗菌活性,表明明胶的固有生物聚合物结构可被设计用于药物或离子释放与表面抗菌防御的结合。
明胶基水凝胶也被广泛探索为抗癌药物的递送平台。其生物相容性、生物降解性以及形成稳定但刺激响应型网络的能力,使其能够在肿瘤部位实现可控和局部药物释放,最小化全身毒性。此外,明胶主链上官能团的存在允许化学修饰以及与靶向配体、纳米颗粒或化疗剂的偶联,进一步增强癌症治疗的特异性和治疗效果。
例如,An等人将阿霉素(DOX)和利福平有效包埋在N'-(2-硝基苄基)-N-丙烯酰甘氨酰胺(NBNAGA)修饰的双增强甲基丙烯酸酯明胶(GelMA)水凝胶中,形成UV交联的光响应网络。该结构结合了化学和物理交联,增强了机械强度和稳定性。由于存在光裂解硝基苄基,疏水药物以温度和光依赖的方式释放。水凝胶表现出可控的药物释放和对大肠杆菌和金黄色葡萄球菌的强抗菌活性,使其在伤口愈合药物递送应用中非常有效。小鼠体内实验证实了加速的皮肤再生,凸显了其作为具有按需疏水药物释放功能的生物相容性伤口敷料的实用性。
一种整合Pluronic基胶束和明胶微凝胶的可注射明胶水凝胶复合材料被合成,用于共递送疏水药物(姜黄素)和亲水药物(5-氟尿嘧啶,5-FU)。明胶组分有助于生物相容性、可注射性和生物降解性,同时作为能够实现可控药物包埋和释放的亲水性基质。Pluronic胶束形成疏水结构域用于姜黄素截留,而微凝胶包埋5-FU,实现适用于协同化疗的双重释放机制。药物释放实验证实5-FU释放持续超过一个月,姜黄素从胶束结构域可控扩散。复合水凝胶对人结直肠腺癌HT-29细胞表现出显著的抗增殖作用,与单药系统相比,细胞死亡增加且增殖减少。明胶的基质完整性和亲水性促进了可注射性和药物稳定性,使该复合材料成为局部联合癌症治疗的强大生物材料。
Ullah等人的研究强调了明胶形成稳定pH敏感性网络的能力,可保护包埋的奥沙利铂(OXP)通过胃肠道,并在结肠环境中实现温和、可控的释放。明胶上官能团的存在允许用丙烯酸(AA)和2-丙烯酰胺-2-甲基丙磺酸(AMPS)进行化学修饰,从而精细调控水凝胶的溶胀、降解和药物释放曲线。载OXP水凝胶对Vero、MCF-7和HCT116细胞系表现出剂量依赖性的细胞毒性,并在动物研究中表现出优异的生物相容性和口服耐受性。该方法旨在改善抗癌药物的靶向和持续递送,减少全身副作用并提高结直肠癌(CRC)治疗的治疗效果。
**6.2. 丝素蛋白**
丝素蛋白是一种天然纤维蛋白,主要由家蚕(如家蚕Bombyx mori)和蜘蛛产生。它具有一系列特性,使其成为生物医学应用的理想材料。它具有生物相容性和酶促生物降解性,确保安全整合到生物系统中而不引起不良反应。此外,丝基材料表现出低免疫原性和无毒性,使其适用于医疗用途。丝素蛋白的关键优势之一是其卓越的机械稳定性,以及可控的格式和尺寸。其可逆溶胀行为允许以干燥状态储存,从而扩展了其在功能化、加工和制备成稳健生物材料方面的潜力。丝素蛋白独特的理化性质源于其蛋白质在初级和二级结构上的组织。高度重复的疏水结晶区域与亲水非结晶结构域之间的相互作用驱动自组装,形成层级结构。这种结构组织导致强烈的物理相互作用和优异的机械性能,包括高强度和韧性。
此外,丝蛋白内的疏水结构域,特别是家蚕丝中的GAGAGS基序和蜘蛛丝中的poly(GA)和poly(A)序列,有助于其结晶含量。这些结构域在增强与药物分子的疏水性相互作用方面发挥关键作用,从而实现药物加载和释放动力学的精确控制。基因工程的进步进一步拓展了丝基生物材料的通用性。通过修饰合成丝基因,研究人员可调控结晶与非结晶结构域之间的平衡,从而精细调节丝的机械性能及其药物结合能力。这种操控丝蛋白分子结构的能力为其在可控药物递送系统中的应用优化开辟了新的可能性。
丝素蛋白主要由两种蛋白质组成:形成纤维结构核心的丝素(fibroin)和将丝素丝粘合在一起的胶状涂层丝胶(sericin)。丝素具有独特的分子结构,富含重复的氨基酸序列(主要是甘氨酸、丙氨酸和丙氨酸),组装成紧密堆积的反平行β-折叠晶体。这种有序结构赋予丝素蛋白卓越的机械强度、韧性和生物相容性。在丝素蛋白(SF)中,蛋白质链采用β-折叠二级结构,提供刚性和稳定性,同时保持一定程度的柔韧性。相比之下,丝胶是一种富含极性基团的亲水性蛋白质,既作为粘合剂又作为丝素核心的保护层。
SF优异的组织相容性和低免疫原性使其不太可能引发显著的免疫反应,并具有一定程度的生物降解性,通常分解为氨基酸或寡肽。降解产物对身体无害,并可对周围组织提供营养和修复益处,使其在组织工程中得到广泛应用。
SF水凝胶可通过物理和化学交联方法合成。物理交联利用丝蛋白对各种分子条件(如pH、剪切和振动)的敏感性,诱导β-折叠结构的形成,从而产生水凝胶。常见的物理交联技术涉及高温和可调pH水平,通常利用循环处理或超声处理。虽然通过物理交联制备的SF水凝胶具有相当的强度,但也存在交联时间长和脆性大等缺点。SF水凝胶的化学交联涉及在聚合物链之间创建共价键。常用的方法包括使用交联剂、光照射和酶促反应。
丝胶是另一种来源于丝的蛋白质,包裹SF并提供保护益处。两者的主要区别在于SF在水中溶胀但不溶解,而丝胶可溶于热水。对丝胶的研究揭示了其作为生物材料的显著优势,包括来源稳定、加工性强、亲水性、低免疫原性、促进细胞增殖的能力、抑制酪氨酸酶活性以及可控降解。在持续释放药物递送系统中,丝胶可通过多种策略被设计成水凝胶,包括物理、化学和光交联方法。最常见的化学方法涉及使用GLU作为交联剂。或者,基于蛋白质在乙醇中不溶的原理,可通过乙醇诱导沉淀结合超声处理制备纯丝胶水凝胶。此外,光交联也已被探索:例如,Qi等人通过甲基丙烯酰化丝胶的UV诱导光交联开发了一种原位水凝胶,展示了一种可控且生物相容的水凝胶形成方法。
由该蛋白质衍生的凝胶对pH变化表现出敏感性,使其适用于开发智能药物递送系统。
**药物递送应用与癌症治疗**
丝基水凝胶已成为药物递送的多功能和生物相容性平台,具有可调的机械性能、可控的降解性以及长期持续释放治疗剂的能力。最近,通过将丝胶与聚己内酯(PCL)在室温下共混,制备了一种软质水凝胶,实现了多孔且非牛顿流变系统,具有良好的吸收能力。此类丝基系统的内部形态(通过扫描电子显微镜表征,图4A)通常显示相互连接的多孔结构。这种孔隙率不仅对药物加载至关重要,还为组织再生所需的气体交换提供了条件。在这些共混物,丝胶的固有性质对水凝胶对革兰氏阳性和革兰氏阴性细菌的抗菌功效有重要贡献,当负载模型药物双氯芬酸钠时进一步增强。从机理角度看,这些水凝胶表现出显著的溶胀和持续可控释放行为。为定量评估这些曲线,实验数据通常拟合数学模型(如图4B所示)。对于丝-PCL系统,释放动力学通常符合Korsmeyer-Peppas模型,其中释放指数常表明为异常转运机制,即通过丝胶丰富孔的Fickian扩散与PCL稳定基质的缓慢侵蚀的结合。这种持续释放,加上丝的天然生物活性,使这些平台在慢性伤口愈合和长期局部药物递送应用中特别有前景。
Ghorbani等人将海藻酸盐与SF结合,通过离子凝胶化和席夫碱反应交联,产生了具有增强的机械强度、稳定性和生物相容性的支架。虽然主要用于骨组织工程,但该系统的特性(孔隙率、持续降解和可调交联密度)也使其适用于局部药物递送,包括骨缺损部位的抗癌治疗。SF通过形成β-折叠结构域稳定网络并调节药物结合,实现治疗分子的可控、位点特异性释放。
Peng等人开发了一种SF基水凝胶,可在生理条件下自组装成可注射的多孔网络。其研究强调了蛋白质的生物相容性、生物降解性和优异的机械性能,使其适用于微创递送。水凝胶整合了碘作为治疗剂,当以持续方式释放时,通过涉及ROS和凋亡机制的途径诱导骨肉瘤细胞凋亡。水凝胶的X射线可见性允许图像引导直接注射到肿瘤部位,促进精确治疗。SF形成稳定、生物相容且可成像的水凝胶,能够在单一系统中结合治疗和诊断功能,使其成为局灶性骨肉瘤治疗的有前景的平台。
除肿瘤治疗的生物活性分子外,丝基水凝胶也被探索为常规化疗药物的递送系统,提供局部给药方法(如瘤内和透皮递送)和静脉注射等全身途径,并采用多种剂型。对于局部药物递送,3D丝植入物已证明能有效控制药物释放速率,包括设计用于持续药物给药的可注射水凝胶。对于全身递送,Fernández-Serra等人的研究描述了SF水凝胶表现出显著的渗透选择性,使药物分子能够可控扩散,使其成为高级神经治疗递送的高效载体。其可调的网络结构允许精确调节药物渗透,确保持续和靶向释放至神经组织,同时最小化全身暴露。此类水凝胶保护包埋剂免受过早降解,维持疾病部位的治疗浓度,并支持神经肿瘤学应用中化疗药物的局部给药。这种选择性屏障功能增强了复杂神经环境中的疗效和安全性。
Jaiswal等人开发了由家蚕丝素蛋白(BMSF)和Antheraea assamensis丝素蛋白(AASF)共混组成的可注射水凝胶,以评估其在乳房切除术后乳腺癌治疗中局部药物递送的潜力。使用MDA-MB-231细胞系设计了3D体外乳房切除术模型,以评估这些水凝胶在递送DOX靶向消除残留乳腺癌细胞方面的功效。此外,通过将地塞米松(DEX)整合到水凝胶系统中,探索了乳房切除术部位脂肪组织再生的潜力。流变学分析表明,BMSF/AASF共混水凝胶具有适用于微创应用的黏弹性和可注射性。水凝胶中DOX的缓慢持续释放导致对MDA-MB-231细胞的有效细胞毒性,体外研究证实了这一点。这些发现凸显了所开发的可注射水凝胶作为局部抗癌药物递送和乳房切除术后乳房重建双重用途系统的潜力。
A. Gangrade和B.B. Mandal开发了一种创新的多孔丝支架,旨在将软水凝胶基质和胃癌(AGS)细胞整合在单一平台内。AGS细胞接种在支架外围,占据多孔结构并形成3D球体。同时,将负载顺铂纳米复合材料的可注射丝水凝胶引入支架中心腔,以评估其在11天内的延长生物活性。这种策略性排列实现了顺铂的持续释放,确保药物对周围球体的长期暴露以增强治疗效果。为模拟癌症复发,在治疗第二天重新接种AGS细胞。实验结果表明,纳米复合丝水凝胶显著延长了顺铂的稳定性和细胞毒性作用。因此,重新接种的AGS细胞无法在支架上存活,凸显了其预防肿瘤复发的潜力。这些方法强调了工程化丝支架在支持靶向和持续化疗同时最小化癌症复发可能性方面的有效性。
**6.3. 大豆蛋白**
大豆蛋白是一种天然来源的聚合物,被广泛探索作为药物递送应用聚合物网络开发的基础材料。其广泛可用性、良好的水溶性以及优异的生物相容性、生物降解性、非免疫原性和抗癌特性使其成为生物医学应用的有前景的候选者。从丰富、成本效益高且可再生的植物基资源中提取,SP主要由两个球蛋白亚基组成:7S(β-伴大豆球蛋白)和11S(大豆球蛋白)。由于其固有的生物活性,SP在粘合剂、水凝胶、塑料、薄膜、涂层和乳化剂的生产中找到了广泛应用。此外,其在生物技术和生物医学工程中的潜力也受到广泛研究。与其他可生物降解聚合物和天然蛋白质相比,SP基质表现出独特的优势,如改善的耐水性、延长的储存稳定性和结构稳健性。这些特性使SP成为设计新型生物材料和医疗器械的宝贵材料,进一步增强了其在生物技术和生物医学研究中的潜力。
大豆分离蛋白(SPI)是大豆蛋白的富集形式,提供极性、非极性和必需氨基酸的平衡混合物,使其适用于各种药物应用。在水环境中,SPI蛋白组装成具有亲水外壳和疏水核心的球形结构,促进稳定性和功能性。在引入沉淀剂或交联剂后,SPI可形成多种结构,包括微球和水凝胶,扩展了其作为药物递送系统载体的潜力。独特的11S/7S球蛋白比例进一步影响与生物医学用途相关的乳化、凝胶化和发泡性能。
**药物递送应用与癌症治疗**
基于SP的杂化水凝胶在药物递送应用中的整合近年来受到广泛关注,这归